Immediate	O
early	O
and	O
early	B-protein
lytic	I-protein
cycle	I-protein
proteins	I-protein
are	O
frequent	O
targets	O
of	O
the	O
Epstein-Barr	O
virus-induced	O
cytotoxic	O
T	O
cell	O
response	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
a	O
human	O
gamma-herpesvirus	O
,	O
can	O
establish	O
both	O
nonproductive	O
(	O
latent	O
)	O
and	O
productive	O
(	O
lytic	O
)	O
infections	O
.	O

Although	O
the	O
CD8+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
latently	B-cell_type
infected	I-cell_type
cells	I-cell_type
is	O
well	O
characterized	O
,	O
very	O
little	O
is	O
known	O
about	O
T	O
cell	O
controls	O
over	O
lytic	O
infection	O
;	O
this	O
imbalance	O
in	O
our	O
understanding	O
belies	O
the	O
importance	O
of	O
virus-replicative	O
lesions	O
in	O
several	O
aspects	O
of	O
EBV	O
disease	O
pathogenesis	O
.	O

The	O
present	O
work	O
shows	O
that	O
the	O
primary	O
CD8+	O
CTL	O
response	O
to	O
EBV	O
in	O
infectious	O
mononucleosis	O
patients	O
contains	O
multiple	O
lytic	O
antigen-specific	O
reactivities	O
at	O
levels	O
at	O
least	O
as	O
high	O
as	O
those	O
seen	O
against	O
latent	B-protein
antigens	I-protein
;	O
similar	O
reactivities	O
are	O
also	O
detectable	O
in	O
CTL	O
memory	O
.	O

Clonal	O
analysis	O
revealed	O
individual	O
responses	O
to	O
the	O
two	O
immediate	B-protein
early	I-protein
proteins	I-protein
BZLF1	B-protein
and	O
BRLF1	B-protein
,	O
and	O
to	O
three	O
(	O
BMLF1	B-protein
,	O
BMRF1	B-protein
,	O
and	O
BALF2	B-protein
)	O
of	O
the	O
six	O
early	B-protein
proteins	I-protein
tested	O
.	O

In	O
several	O
cases	O
,	O
the	O
peptide	O
epitope	O
and	O
HLA-restricting	O
determinant	O
recognized	O
by	O
these	O
CTLs	B-cell_type
has	O
been	O
defined	O
,	O
one	O
unusual	O
feature	O
being	O
the	O
number	O
of	O
responses	O
restricted	O
through	O
HLA-C	B-DNA
alleles	I-DNA
.	O

The	O
work	O
strongly	O
suggests	O
that	O
EBV-replicative	O
lesions	O
are	O
subject	O
to	O
direct	O
CTL	O
control	O
in	O
vivo	O
and	O
that	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
are	O
frequently	O
the	O
immunodominant	O
targets	O
.	O

This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen-processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	B-protein
early	I-protein
and	I-protein
early	I-protein
proteins	I-protein
much	O
less	O
immunogenic	O
.	O

The	O
unique	O
capacity	O
of	O
gamma-herpesvirus	O
to	O
amplify	O
the	O
viral	O
load	O
in	O
vivo	O
through	O
a	O
latent	O
growth-transforming	O
infection	O
may	O
have	O
rendered	O
these	O
agents	O
less	O
dependent	O
upon	O
viral	O
replication	O
as	O
a	O
means	O
of	O
successfully	O
colonizing	O
their	O
hosts	O
.	O

Immediate	NULL
Early	NULL
and	NULL
Early	NULL
Lytic	NULL
Cycle	NULL
Proteins	NULL
Are	NULL
Frequent	NULL
Targets	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
Virus-induced	NULL
Cytotoxic	NULL
T	NULL
Cell	NULL
Response	NULL
By	NULL
N.M.	NULL
Steven	NULL
,	NULL
*	NULL
N.E	NULL
.	NULL

Annels	NULL
,	NULL
*	NULL
A.	NULL
Kumar	NULL
,	NULL
*	NULL
A.M.	NULL
Leese	NULL
,	NULL
*	NULL
M.G	NULL
.	NULL

Kurilla	NULL
,	NULL
*	NULL
and	NULL
A.B	NULL
.	NULL

R	NULL
ickinson*	NULL
From	NULL
the	NULL
*	NULL
Cancer	NULL
R	NULL
esearch	NULL
Campaign	NULL
Institute	NULL
for	NULL
C	NULL
ancer	NULL
Studies	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Birmingham	NULL
,	NULL
B15	NULL
2TT	NULL
,	NULL
U.	NULL
K.	NULL
;	NULL
and	NULL
the	NULL
*Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Virginia	NULL
,	NULL
Charlottesville	NULL
Virginia	NULL
22908	NULL
Sum	NULL
m	NULL
ary	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
,	NULL
a	NULL
human	NULL
y-herpesvirus	NULL
,	NULL
can	NULL
establish	NULL
both	NULL
nonproductive	NULL
(	NULL
latent	NULL
)	NULL
and	NULL
productive	NULL
(	NULL
Iytic	NULL
)	NULL
infections	NULL
.	NULL

Although	NULL
the	NULL
CD8*	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
response	NULL
to	NULL
latently	NULL
infected	NULL
cells	NULL
is	NULL
well	NULL
characterized	NULL
,	NULL
very	NULL
little	NULL
is	NULL
known	NULL
about	NULL
T	NULL
cell	NULL
controls	NULL
over	NULL
lytic	NULL
infection	NULL
;	NULL
this	NULL
imbalance	NULL
in	NULL
our	NULL
understanding	NULL
belies	NULL
the	NULL
importance	NULL
of	NULL
virus-replicative	NULL
lesions	NULL
in	NULL
several	NULL
aspects	NULL
of	NULL
EBV	NULL
disease	NULL
pathogenesis	NULL
.	NULL

The	NULL
present	NULL
work	NULL
shows	NULL
that	NULL
the	NULL
primary	NULL
CD8+*	NULL
CTL	NULL
response	NULL
to	NULL
EBV	NULL
in	NULL
infectious	NULL
mononucleosis	NULL
patients	NULL
contains	NULL
multiple	NULL
lytic	NULL
antigen-specific	NULL
reactivities	NULL
at	NULL
levels	NULL
at	NULL
least	NULL
as	NULL
high	NULL
as	NULL
those	NULL
seen	NULL
against	NULL
latent	NULL
antigens	NULL
;	NULL
similar	NULL
reactivities	NULL
are	NULL
also	NULL
detectable	NULL
in	NULL
CTL	NULL
memory	NULL
.	NULL

Clonal	NULL
analysis	NULL
revealed	NULL
individual	NULL
responses	NULL
to	NULL
the	NULL
two	NULL
immediate	NULL
early	NULL
proteins	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
,	NULL
and	NULL
to	NULL
three	NULL
(	NULL
BMLF1	NULL
,	NULL
BMRFI1	NULL
,	NULL
and	NULL
BALF	NULL
?	NULL
)	NULL

of	NULL
the	NULL
six	NULL
early	NULL
proteins	NULL
tested	NULL
.	NULL

In	NULL
several	NULL
cases	NULL
,	NULL
the	NULL
peptide	NULL
epitope	NULL
and	NULL
HLA-restrict-ing	NULL
determinant	NULL
recognized	NULL
by	NULL
these	NULL
CTLs	NULL
has	NULL
been	NULL
defined	NULL
,	NULL
one	NULL
unusual	NULL
feature	NULL
being	NULL
the	NULL
number	NULL
of	NULL
responses	NULL
restricted	NULL
through	NULL
HLA-C	NULL
alleles	NULL
.	NULL

The	NULL
work	NULL
strongly	NULL
suggests	NULL
that	NULL
EBV-replicative	NULL
lesions	NULL
are	NULL
subject	NULL
to	NULL
direct	NULL
CTL	NULL
control	NULL
in	NULL
vivo	NULL
and	NULL
that	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
proteins	NULL
are	NULL
frequently	NULL
the	NULL
immunodominant	NULL
targets	NULL
.	NULL

This	NULL
contrasts	NULL
with	NULL
findings	NULL
in	NULL
«	NULL
-	NULL
and	NULL
B-herpesvirus	NULL
systems	NULL
(	NULL
herpes	NULL
simplex	NULL
,	NULL
cytomegalovirus	NULL
)	NULL
where	NULL
viral	NULL
interference	NULL
with	NULL
the	NULL
anti-gen-processing	NULL
pathway	NULL
during	NULL
lytic	NULL
infection	NULL
renders	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
proteins	NULL
much	NULL
less	NULL
immunogenic	NULL
.	NULL

The	NULL
unique	NULL
capacity	NULL
of	NULL
y-herpesvirus	NULL
to	NULL
amplify	NULL
the	NULL
viral	NULL
load	NULL
in	NULL
vivo	NULL
through	NULL
a	NULL
latent	NULL
growth-transforming	NULL
infection	NULL
may	NULL
have	NULL
rendered	NULL
these	NULL
agents	NULL
less	NULL
dependent	NULL
upon	NULL
viral	NULL
replication	NULL
as	NULL
a	NULL
means	NULL
of	NULL
successfully	NULL
colonizing	NULL
their	NULL
hosts	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
,	NULL
a	NULL
y-herpesvirus	NULL
widespread	NULL
in	NULL
human	NULL
populations	NULL
,	NULL
is	NULL
carried	NULL
as	NULL
a	NULL
life-long	NULL
infection	NULL
in	NULL
the	NULL
great	NULL
majority	NULL
of	NULL
immunocompetent	NULL
individuals	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Viral	NULL
infection	NULL
and	NULL
persistence	NULL
are	NULL
accomplished	NULL
through	NULL
a	NULL
balance	NULL
of	NULL
productive	NULL
(	NULL
lytic	NULL
)	NULL
and	NULL
nonproductive	NULL
(	NULL
latent	NULL
)	NULL
infections	NULL
.	NULL

After	NULL
oral	NULL
transmission	NULL
,	NULL
a	NULL
primary	NULL
focus	NULL
of	NULL
virus	NULL
replication	NULL
is	NULL
established	NULL
in	NULL
oropharyngeal	NULL
epithelium	NULL
(	NULL
2	NULL
)	NULL
and/	NULL
or	NULL
local	NULL
mucosa-associated	NULL
lymphoid	NULL
tissue	NULL
(	NULL
3	NULL
)	NULL
,	NULL
with	NULL
infectious	NULL
virus	NULL
being	NULL
shed	NULL
into	NULL
the	NULL
throat	NULL
.	NULL

At	NULL
the	NULL
same	NULL
time	NULL
,	NULL
the	NULL
virus	NULL
colonizes	NULL
the	NULL
generalized	NULL
B	NULL
cell	NULL
pool	NULL
through	NULL
a	NULL
latent	NULL
growth-transforming	NULL
infection	NULL
(	NULL
4	NULL
)	NULL
,	NULL
thereby	NULL
establishing	NULL
a	NULL
reservoir	NULL
of	NULL
virus	NULL
genome-positive	NULL
cells	NULL
upon	NULL
which	NULL
long-term	NULL
virus	NULL
persistence	NULL
depends	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

Subsequent	NULL
reactivation	NULL
of	NULL
such	NULL
B	NULL
cells	NULL
from	NULL
latency	NULL
into	NULL
lytic	NULL
cycle	NULL
can	NULL
then	NULL
initiate	NULL
secondary	NULL
foci	NULL
of	NULL
virus	NULL
replication	NULL
at	NULL
pharyngeal	NULL
sites	NULL
.	NULL

There	NULL
is	NULL
strong	NULL
evidence	NULL
that	NULL
the	NULL
size	NULL
of	NULL
the	NULL
latently	NULL
infected	NULL
B	NULL
cell	NULL
pool	NULL
is	NULL
kept	NULL
under	NULL
control	NULL
by	NULL
host	NULL
CD8*	NULL
CTL	NULL
responses	NULL
both	NULL
during	NULL
primary	NULL
infection	NULL
(	NULL
7	NULL
)	NULL
and	NULL
throughout	NULL
the	NULL
life-long	NULL
carrier	NULL
state	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
the	NULL
likely	NULL
importance	NULL
of	NULL
virus	NULL
replicative	NULL
lesions	NULL
in	NULL
several	NULL
as	NULL
1605	NULL
pects	NULL
of	NULL
EBV-associated	NULL
disease	NULL
pathogenesis	NULL
(	NULL
10-13	NULL
)	NULL
,	NULL
virtually	NULL
nothing	NULL
is	NULL
known	NULL
about	NULL
T	NULL
cell	NULL
controls	NULL
which	NULL
might	NULL
be	NULL
exercised	NULL
over	NULL
lytic	NULL
infections	NULL
.	NULL

This	NULL
contrasts	NULL
with	NULL
the	NULL
situation	NULL
for	NULL
herpesviruses	NULL
of	NULL
the	NULL
«	NULL
and	NULL
B	NULL
subfamilies	NULL
,	NULL
such	NULL
as	NULL
HSV	NULL
and	NULL
CMV	NULL
,	NULL
where	NULL
lytic	NULL
antigen-specific	NULL
CD8*	NULL
CTL	NULL
responses	NULL
have	NULL
been	NULL
detected	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
these	NULL
tend	NULL
to	NULL
be	NULL
directed	NULL
not	NULL
against	NULL
immediate	NULL
early	NULL
or	NULL
early	NULL
antigens	NULL
of	NULL
the	NULL
lytic	NULL
cycle	NULL
,	NULL
but	NULL
against	NULL
some	NULL
of	NULL
the	NULL
virus	NULL
structural	NULL
proteins	NULL
that	NULL
are	NULL
delivered	NULL
into	NULL
the	NULL
cell	NULL
by	NULL
the	NULL
incoming	NULL
virus	NULL
particle	NULL
(	NULL
15	NULL
,	NULL
17	NULL
)	NULL
;	NULL
this	NULL
focusing	NULL
of	NULL
the	NULL
response	NULL
on	NULL
preformed	NULL
antigens	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
some	NULL
of	NULL
the	NULL
first	NULL
viral	NULL
proteins	NULL
to	NULL
be	NULL
expressed	NULL
de	NULL
novo	NULL
in	NULL
HSV-	NULL
or	NULL
CMV-infected	NULL
cells	NULL
actually	NULL
inhibit	NULL
the	NULL
pathway	NULL
of	NULL
antigen	NULL
presentation	NULL
to	NULL
CD8*	NULL
lymphocytes	NULL
(	NULL
15	NULL
,	NULL
17-22	NULL
)	NULL
.	NULL

Whether	NULL
a	NULL
similar	NULL
situation	NULL
pertains	NULL
with	NULL
EBV	NULL
is	NULL
therefore	NULL
of	NULL
particular	NULL
interest	NULL
.	NULL

The	NULL
current	NULL
imbalance	NULL
in	NULL
our	NULL
understanding	NULL
of	NULL
EBV-induced	NULL
CTL	NULL
responses	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
latent	NULL
infections	NULL
of	NULL
B	NULL
lymphocytes	NULL
can	NULL
readily	NULL
be	NULL
established	NULL
in	NULL
vitro	NULL
in	NULL
the	NULL
form	NULL
of	NULL
virus-transformed	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

©	NULL
The	NULL
R	NULL
ockefeller	NULL
University	NULL
Press	NULL
»	NULL
0022-1007/	NULL
97/	NULL
05/	NULL
1605/	NULL
13	NULL
$	NULL
2.00	NULL
Volume	NULL
185	NULL
,	NULL
Number	NULL
9	NULL
,	NULL
May	NULL
5	NULL
,	NULL
1997	NULL
1605-1617	NULL
(	NULL
LCLs	NULL
)	NULL
!	NULL

expressing	NULL
the	NULL
full	NULL
range	NULL
of	NULL
virus	NULL
latent	NULL
proteins	NULL
,	NULL
namely	NULL
,	NULL
the	NULL
EB	NULL
nuclear	NULL
antigens	NULL
(	NULL
EBN	NULL
As	NULL
)	NULL
1	NULL
,	NULL
2	NULL
,	NULL
3A	NULL
,	NULL
3B	NULL
,	NULL
3C	NULL
,	NULL
-LP	NULL
,	NULL
and	NULL
the	NULL
latent	NULL
membrane	NULL
proteins	NULL
LMPs	NULL
1	NULL
and	NULL
2	NULL
(	NULL
1	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
no	NULL
naturally	NULL
permissive	NULL
system	NULL
for	NULL
EBV	NULL
replication	NULL
exists	NULL
in	NULL
vitro	NULL
and	NULL
so	NULL
studies	NULL
of	NULL
lytic	NULL
cycle	NULL
have	NULL
had	NULL
to	NULL
focus	NULL
on	NULL
the	NULL
small	NULL
numbers	NULL
of	NULL
cells	NULL
within	NULL
LCLs	NULL
which	NULL
activate	NULL
virus	NULL
replication	NULL
either	NULL
spontaneously	NULL
or	NULL
after	NULL
treatment	NULL
with	NULL
inducing	NULL
agents	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Co-cultivating	NULL
T	NULL
cells	NULL
from	NULL
an	NULL
immune	NULL
individual	NULL
with	NULL
autologous	NULL
LCL	NULL
stimulators	NULL
has	NULL
made	NULL
possible	NULL
a	NULL
quite	NULL
detailed	NULL
analysis	NULL
of	NULL
latent	NULL
cycle-specific	NULL
CTL	NULL
responses	NULL
across	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
restriction	NULL
elements	NULL
and	NULL
has	NULL
shown	NULL
an	NULL
unusually	NULL
marked	NULL
focusing	NULL
of	NULL
responses	NULL
on	NULL
immunodominant	NULL
epitopes	NULL
from	NULL
the	NULL
EBN	NULL
3B	NULL
,	NULL
3C	NULL
subset	NULL
of	NULL
latent	NULL
proteins	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
24	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
however	NULL
,	NULL
such	NULL
in	NULL
vitro	NULL
reactivation	NULL
protocols	NULL
have	NULL
not	NULL
revealed	NULL
obvious	NULL
lytic	NULL
cycle-specific	NULL
components	NULL
of	NULL
the	NULL
response	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
addressed	NULL
the	NULL
question	NULL
of	NULL
lytic	NULL
antigen-specific	NULL
reactivities	NULL
in	NULL
another	NULL
way	NULL
.	NULL

The	NULL
work	NULL
was	NULL
prompted	NULL
by	NULL
our	NULL
recent	NULL
observation	NULL
that	NULL
the	NULL
circulating	NULL
CD8*	NULL
T	NULL
cells	NULL
of	NULL
infectious	NULL
mononucleosis	NULL
(	NULL
IM	NULL
)	NULL
patients	NULL
undergoing	NULL
primary	NULL
EBV	NULL
infection	NULL
contained	NULL
a	NULL
variety	NULL
of	NULL
latent	NULL
cycle-specific	NULL
effectors	NULL
which	NULL
were	NULL
not	NULL
only	NULL
detectable	NULL
in	NULL
ex	NULL
vivo	NULL
cytotoxicity	NULL
assays	NULL
using	NULL
antigen-	NULL
or	NULL
peptide	NULL
epitope-sensitized	NULL
targets	NULL
,	NULL
but	NULL
also	NULL
could	NULL
be	NULL
separated	NULL
into	NULL
individual	NULL
reactivities	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
in	NULL
vitro	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
efficiency	NULL
of	NULL
the	NULL
system	NULL
suggested	NULL
to	NULL
us	NULL
that	NULL
any	NULL
co-resident	NULL
lytic	NULL
cycle-specific	NULL
effectors	NULL
should	NULL
also	NULL
be	NULL
detectable	NULL
using	NULL
such	NULL
an	NULL
approach	NULL
.	NULL

As	NULL
with	NULL
other	NULL
herpesvi-ruses	NULL
,	NULL
EBV	NULL
replication	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
large	NULL
number	NULL
of	NULL
(	NULL
up	NULL
to	NULL
80	NULL
)	NULL
lytic	NULL
cycle	NULL
proteins	NULL
which	NULL
can	NULL
be	NULL
classified	NULL
into	NULL
three	NULL
temporal	NULL
phases	NULL
;	NULL
immediate	NULL
early	NULL
,	NULL
early	NULL
,	NULL
and	NULL
late	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
focused	NULL
our	NULL
attention	NULL
on	NULL
the	NULL
two	NULL
best	NULL
known	NULL
EBV	NULL
immediate	NULL
early	NULL
proteins	NULL
,	NULL
BZLFI	NULL
and	NULL
BRLFI	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
,	NULL
and	NULL
on	NULL
six	NULL
representative	NULL
early	NULL
proteins	NULL
BMLFI	NULL
,	NULL
BMRFI	NULL
,	NULL
BHLFI	NULL
,	NULL
BHRFI	NULL
,	NULL
BALF2	NULL
,	NULL
and	NULL
BALF5	NULL
,	NULL
several	NULL
of	NULL
which	NULL
are	NULL
directly	NULL
transactivated	NULL
by	NULL
BZLF1/	NULL
BRLFI	NULL
during	NULL
the	NULL
progress	NULL
of	NULL
the	NULL
lytic	NULL
cycle	NULL
(	NULL
27-29	NULL
)	NULL
.	NULL

The	NULL
initial	NULL
stages	NULL
of	NULL
the	NULL
work	NULL
were	NULL
greatly	NULL
assisted	NULL
by	NULL
an	NULL
observation	NULL
from	NULL
Bogedain	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
)	NULL
who	NULL
used	NULL
pooled	NULL
peptides	NULL
from	NULL
the	NULL
BZLF1	NULL
sequence	NULL
as	NULL
an	NULL
in	NULL
vitro	NULL
stimulus	NULL
to	NULL
T	NULL
cells	NULL
from	NULL
virus	NULL
immune	NULL
donors	NULL
and	NULL
in	NULL
that	NULL
way	NULL
identified	NULL
a	NULL
8-mer	NULL
BZLF1	NULL
peptide	NULL
RAKFKQLL	NULL
that	NULL
appeared	NULL
to	NULL
be	NULL
recognized	NULL
by	NULL
HLA-B8-restricted	NULL
memory	NULL
CTLs	NULL
.	NULL

This	NULL
remains	NULL
the	NULL
only	NULL
indication	NULL
in	NULL
the	NULL
literature	NULL
that	NULL
EBV	NULL
lytic	NULL
infections	NULL
might	NULL
induce	NULL
a	NULL
CD8*	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
EBV	NULL
infection	NULL
induces	NULL
abundant	NULL
CTL	NULL
reactivities	NULL
to	NULL
a	NULL
range	NULL
of	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
lytic	NULL
cycle	NULL
proteins	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Donors	NULL
.	NULL

Six	NULL
IM	NULL
patients	NULL
,	NULL
identified	NULL
on	NULL
clinical	NULL
grounds	NULL
and	NULL
by	NULL
heterophile	NULL
antibody	NULL
positivity	NULL
,	NULL
were	NULL
sampled	NULL
during	NULL
the	NULL
first	NULL
10	NULL
d	NULL
'	NULL
A	NULL
bbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
EBN	NULL
A	NULL
,	NULL
EB	NULL
nuclear	NULL
antigen	NULL
;	NULL
IM	NULL
,	NULL
infectious	NULL
mononucleosis	NULL
;	NULL
LCL	NULL
,	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
TK	NULL
,	NULL
thymidine	NULL
kinase	NULL
;	NULL
vace	NULL
,	NULL
vaccinia	NULL
.	NULL

1606	NULL
of	NULL
illness	NULL
and	NULL
,	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
on	NULL
a	NULL
second	NULL
occasion	NULL
9-21	NULL
mo	NULL
after	NULL
the	NULL
resolution	NULL
of	NULL
symptoms	NULL
.	NULL

Two	NULL
healthy	NULL
virus	NULL
carriers	NULL
,	NULL
CG	NULL
and	NULL
KG	NULL
,	NULL
were	NULL
also	NULL
studied	NULL
.	NULL

The	NULL
donors	NULL
were	NULL
HLA	NULL
typed	NULL
either	NULL
by	NULL
serotyping	NULL
in	NULL
microcytotoxicity	NULL
assays	NULL
(	NULL
lymphotype	NULL
AB120	NULL
;	NULL
Bio-test	NULL
,	NULL
Denville	NULL
,	NULL
NJ	NULL
)	NULL
or	NULL
by	NULL
genotyping	NULL
(	NULL
courtesy	NULL
of	NULL
Dr.	NULL
M.	NULL
Hatha-way	NULL
,	NULL
Liver	NULL
Laboratories	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Birmingham	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

The	NULL
HLA-A	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
,	NULL
where	NULL
appropriate	NULL
,	NULL
-C	NULL
types	NULL
were	NULL
as	NULL
follows	NULL
.	NULL

IM53	NULL
:	NULL
A3	NULL
,	NULL
A30	NULL
,	NULL
B8	NULL
,	NULL
B18	NULL
,	NULL
C5	NULL
,	NULL
C7	NULL
;	NULL
IM55	NULL
:	NULL
A24	NULL
,	NULL
A32	NULL
,	NULL
B13	NULL
,	NULL
B60	NULL
,	NULL
C3	NULL
,	NULL
C6	NULL
;	NULL
IM59	NULL
:	NULL
Al	NULL
,	NULL
A2	NULL
,	NULL
B8	NULL
,	NULL
B62	NULL
;	NULL
IM61	NULL
:	NULL
A2.01	NULL
,	NULL
A3	NULL
,	NULL
B7	NULL
,	NULL
B44	NULL
,	NULL
C5	NULL
,	NULL
C7	NULL
;	NULL
IM63	NULL
:	NULL
Al	NULL
,	NULL
A2.05	NULL
,	NULL
B8	NULL
,	NULL
B49	NULL
,	NULL
C6	NULL
,	NULL
C7	NULL
;	NULL
IM69	NULL
:	NULL
A2.01	NULL
,	NULL
A32	NULL
,	NULL
B7	NULL
,	NULL
B63	NULL
;	NULL
KG	NULL
:	NULL
A30	NULL
,	NULL
A32	NULL
,	NULL
B44	NULL
,	NULL
B47	NULL
,	NULL
C5	NULL
,	NULL
C6	NULL
;	NULL
CG	NULL
:	NULL
A25	NULL
,	NULL
A28	NULL
,	NULL
B39	NULL
,	NULL
B62	NULL
.	NULL

LCL	NULL
Establishment	NULL
and	NULL
Preparation	NULL
of	NULL
CTL	NULL
Effetors	NULL
.	NULL

-	NULL
Heparinized	NULL
whole	NULL
blood	NULL
(	NULL
50	NULL
ml	NULL
)	NULL
was	NULL
diluted	NULL
1:1	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
and	NULL
separated	NULL
by	NULL
centrifugation	NULL
on	NULL
lymphoprep	NULL
(	NULL
Nycomed	NULL
Pharma	NULL
,	NULL
O	NULL
slo	NULL
,	NULL
Norway	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
were	NULL
harvested	NULL
from	NULL
the	NULL
interface	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
cryopreserved	NULL
within	NULL
3	NULL
h	NULL
of	NULL
venesection	NULL
.	NULL

Aliquots	NULL
of	NULL
PBMCs	NULL
were	NULL
used	NULL
for	NULL
the	NULL
establishment	NULL
of	NULL
an	NULL
EBV-transformed	NULL
LCL	NULL
either	NULL
by	NULL
spontaneous	NULL
transformation	NULL
with	NULL
the	NULL
donor	NULL
's	NULL
own	NULL
virus	NULL
strain	NULL
or	NULL
by	NULL
addition	NULL
of	NULL
ex-ogenous	NULL
EBV	NULL
(	NULL
B95.8	NULL
strain	NULL
)	NULL
;	NULL
for	NULL
this	NULL
,	NULL
the	NULL
culture	NULL
medium	NULL
was	NULL
RPMI	NULL
1640	NULL
+	NULL
2	NULL
mM	NULL
glutamine	NULL
+	NULL
10	NULL
%	NULL
vol/	NULL
vol	NULL
FCS	NULL
,	NULL
initially	NULL
supplemented	NULL
with	NULL
0.1	NULL
ug/ml	NULL
cyclosporin	NULL
A	NULL
.	NULL

The	NULL
proportion	NULL
of	NULL
cells	NULL
spontaneously	NULL
entering	NULL
lytic	NULL
cycle	NULL
in	NULL
such	NULL
lines	NULL
was	NULL
determined	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
staining	NULL
using	NULL
the	NULL
BZLF1-specific	NULL
mAb	NULL
BZ-1	NULL
(	NULL
31	NULL
)	NULL
and	NULL
the	NULL
virus	NULL
capsid	NULL
antigen-specific	NULL
mAb	NULL
V3	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Acute	NULL
IM	NULL
PBMC	NULL
effectors	NULL
for	NULL
use	NULL
in	NULL
ex	NULL
vivo	NULL
cytotoxicity	NULL
as	NULL
says	NULL
were	NULL
thawed	NULL
in	NULL
IL-2-enriched	NULL
medium	NULL
(	NULL
see	NULL
below	NULL
)	NULL
and	NULL
used	NULL
either	NULL
directly	NULL
or	NULL
after	NULL
initial	NULL
depletion	NULL
of	NULL
CD16+*	NULL
NK	NULL
cells	NULL
For	NULL
the	NULL
latter	NULL
,	NULL
PBMCs	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
5	NULL
pl	NULL
anti-CD16	NULL
IgM	NULL
mAb	NULL
(	NULL
leu	NULL
11b	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
/	NULL
10°	NULL
cells	NULL
,	NULL
washed	NULL
once	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
IL-2-enriched	NULL
medium	NULL
containing	NULL
5:1	NULL
vol/	NULL
vol	NULL
rabbit	NULL
complement	NULL
(	NULL
CO999f	NULL
;	NULL
Harlan	NULL
Sera-Lab	NULL
,	NULL
Loughborough	NULL
,	NULL
U.K.	NULL
)	NULL
,	NULL
and	NULL
then	NULL
washed	NULL
twice	NULL
before	NULL
use	NULL
in	NULL
the	NULL
cytotoxicity	NULL
assay	NULL
.	NULL

Primary	NULL
polyclonal	NULL
CTL	NULL
lines	NULL
were	NULL
established	NULL
by	NULL
stimulating	NULL
thawed	NULL
IM	NULL
PBMCs	NULL
on	NULL
day	NULL
0	NULL
and	NULL
weekly	NULL
thereafter	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
at	NULL
an	NULL
effector	NULL
,	NULL
stimulator	NULL
ratio	NULL
of	NULL
4:1	NULL
in	NULL
RPMI	NULL
1640	NULL
+	NULL
2	NULL
mM	NULL
glutamine	NULL
+	NULL
10	NULL
%	NULL
vol/	NULL
vol	NULL
FCS	NULL
,	NULL
1	NULL
%	NULL
vol/	NULL
vol	NULL
human	NULL
se-rum	NULL
,	NULL
30	NULL
%	NULL
vol/	NULL
vol	NULL
supernatant	NULL
from	NULL
the	NULL
IL-2-secreting	NULL
cell	NULL
line	NULL
MLA-	NULL
144	NULL
(	NULL
MLA-SN	NULL
)	NULL
,	NULL
and	NULL
100	NULL
U/	NULL
ml	NULL
of	NULL
recombinant	NULL
IL-2	NULL
(	NULL
here-after	NULL
called	NULL
IL-2-enriched	NULL
medium	NULL
)	NULL
.	NULL

Primary	NULL
CTL	NULL
clones	NULL
were	NULL
established	NULL
by	NULL
limiting	NULL
dilution	NULL
of	NULL
thawed	NULL
IM	NULL
PBMCs	NULL
directly	NULL
into	NULL
IL-2-enriched	NULL
medium	NULL
at	NULL
0.3-100	NULL
celly	NULL
0.2	NULL
ml	NULL
round-bot-tomed	NULL
well	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
irradiated	NULL
preactivated	NULL
allogeneic	NULL
PBMC	NULL
feeders	NULL
(	NULL
10	NULL
%	NULL
/	NULL
ml	NULL
)	NULL
either	NULL
alone	NULL
,	NULL
with	NULL
irradiated	NULL
autologous	NULL
LCL	NULL
cells	NULL
(	NULL
10	NULL
%	NULL
/	NULL
ml	NULL
)	NULL
,	NULL
or	NULL
with	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
OKT3	NULL
;	NULL
Unipath	NULL
,	NULL
Basingstoke	NULL
,	NULL
U.K.	NULL
)	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
50	NULL
ng/ml	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
growing	NULL
microcultures	NULL
were	NULL
further	NULL
expanded	NULL
by	NULL
transfer	NULL
into	NULL
2-ml	NULL
wells	NULL
using	NULL
the	NULL
same	NULL
stimulation	NULL
protocol	NULL
as	NULL
before	NULL
.	NULL

Feeder	NULL
cells	NULL
were	NULL
from	NULL
pooled	NULL
fresh	NULL
buffy	NULL
coats	NULL
(	NULL
National	NULL
Blood	NULL
Service	NULL
,	NULL
Birmingham	NULL
,	NULL
U.K.	NULL
)	NULL
and	NULL
were	NULL
incubated	NULL
with	NULL
PHA	NULL
at	NULL
10	NULL
pg/ml	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
then	NULL
washed	NULL
five	NULL
times	NULL
before	NULL
irradiation	NULL
and	NULL
use	NULL
.	NULL

In	NULL
some	NULL
cases	NULL
,	NULL
CTL	NULL
clones	NULL
were	NULL
also	NULL
established	NULL
from	NULL
14-d	NULL
cultures	NULL
of	NULL
the	NULL
polyclonal	NULL
CTL	NULL
line	NULL
or	NULL
from	NULL
limiting	NULL
dilution	NULL
cultures	NULL
by	NULL
reseeding	NULL
at	NULL
0.3-3	NULL
celly	NULL
well	NULL
using	NULL
the	NULL
conditions	NULL
outlined	NULL
above	NULL
.	NULL

Memory	NULL
CTL	NULL
clones	NULL
were	NULL
established	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
PBMCs	NULL
from	NULL
postconvalescent	NULL
IM	NULL
donors	NULL
or	NULL
from	NULL
long-term	NULL
virus	NULL
carriers	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
at	NULL
a	NULL
responder	NULL
stimulator	NULL
ratio	NULL
of	NULL
40:1	NULL
,	NULL
and	NULL
then	NULL
restimulated	NULL
10	NULL
d	NULL
later	NULL
at	NULL
a	NULL
responder/	NULL
stimulator	NULL
ratio	NULL
of	NULL
4:1	NULL
.	NULL

Cloning	NULL
took	NULL
place	NULL
4	NULL
d	NULL
later	NULL
by	NULL
seeding	NULL
at	NULL
CTL	NULL
Responses	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Lytic	NULL
Cycle	NULL
Antigens	NULL
A	NULL
-	NULL
IMS3	NULL
ex	NULL
vivo	NULL
effectors	NULL
B	NULL
-	NULL
IMS59	NULL
ex	NULL
vivo	NULL
effectors	NULL
30	NULL
6o	NULL
¥	NULL
&	NULL
Z	NULL
f~	NULL
3	NULL
8	NULL
F	NULL
315	NULL
230	NULL
ﬁ	NULL
‘	NULL
i	NULL
'	NULL
B	NULL
A	NULL
2	NULL
:	NULL
|S	NULL
AG	NULL
#	NULL
g~	NULL
g~	NULL
ZB	NULL
N	NULL
EBNA	NULL
_	NULL
EBNA	NULL
_	NULL
BZLFI	NULL
no	NULL
EBNA	NULL
_	NULL
EBNA	NULL
-	NULL
BZLPI	NULL
no	NULL
158-166	NULL
-	NULL
325-333	NULL
190-197	NULL
-	NULL
pepude	NULL
|	NULL
158-166	NULL
.	NULL

325-333	NULL
190-197	NULL
_	NULL
peptide	NULL
Figure	NULL
1	NULL
.	NULL

Screening	NULL
of	NULL
IM	NULL
primary	NULL
-	NULL
effectors	NULL
immediately	NULL
ex	NULL
vivo	NULL
(	NULL
A-C	NULL
)	NULL
and	NULL
after	NULL
LCL	NULL
stimulation	NULL
in	NULL
vitro	NULL
and	NULL
expansion	NULL
to	NULL
a	NULL
polyclonal	NULL
CTL	NULL
line	NULL
(	NULL
D-F	NULL
)	NULL
.	NULL

Epitope-specific	NULL
reactivities	NULL
were	NULL
detected	NULL
using	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
pretreated	NULL
with	NULL
the	NULL
denoted	NULL
epitope	NULL
peptides	NULL
at	NULL
2	NULL
pg/ml	NULL
or	NULL
with	NULL
an	NULL
equivalent	NULL
_	NULL
concentration	NULL
_	NULL
of	NULL
DMSO	NULL
solvent	NULL
alone	NULL
(	NULL
``	NULL
no	NULL
peptide	NULL
``	NULL
control	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percentage	NULL
specific	NULL
lysis	NULL
in	NULL
7-h	NULL
chromium	NULL
release	NULL
assays	NULL
for	NULL
(	NULL
A	NULL
)	NULL
IM53	NULL
effectors	NULL
C	NULL
_	NULL
IM63	NULL
ex	NULL
vivo	NULL
effectors	NULL
40	NULL
20	NULL
%	NULL
specific	NULL
lysis	NULL
Is	NULL
CLZ	NULL
LLL	NULL
4	NULL
C	NULL
5	NULL
f	NULL
EBNA	NULL
EBNA	NULL
_	NULL
BZLEI	NULL
158-166	NULL
-	NULL
325-333	NULL
190-197	NULL
-	NULL
peptide	NULL
|	NULL
|	NULL
autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
D	NULL
-	NULL
IM53	NULL
CTL	NULL
line	NULL
E	NULL
70	NULL
IM59	NULL
CTL	NULL
line	NULL
co	NULL
7	NULL
%	NULL
specific	NULL
lysis	NULL
o	NULL
3	NULL
%	NULL
specific	NULL
lysi	NULL
a	NULL
manage	NULL
lysis	NULL
&	NULL
°	NULL
``	NULL
-EBNA	NULL
'	NULL
EBNA	NULL
-	NULL
BZLF	NULL
]	NULL
no	NULL
°	NULL
EBNaA	NULL
\	NULL
158-166	NULL
-	NULL
325-333	NULL
190-197	NULL
-	NULL
peplide	NULL
f	NULL
\	NULL
158-166	NULL
EBNA	NULL
_	NULL
BZLFI	NULL
no	NULL
325-333	NULL
190-197	NULL
_	NULL
peptide	NULL
f	NULL
tested	NULL
ex	NULL
vivo	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
60:1	NULL
(	NULL
EM	NULL
)	NULL
and	NULL
30:1	NULL
(	NULL
2	NULL
)	NULL
;	NULL
(	NULL
B	NULL
)	NULL
F	NULL
_	NULL
IM63	NULL
CTL	NULL
line	NULL
IMS59	NULL
effectors	NULL
tested	NULL
ex	NULL
vivo	NULL
at	NULL
70	NULL
E/T	NULL
ratios	NULL
of	NULL
80:1	NULL
(	NULL
ER	NULL
)	NULL
,	NULL
40:1	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
20:1	NULL
(	NULL
RY	NULL
)	NULL
;	NULL
(	NULL
C	NULL
)	NULL
IM63	NULL
effectors	NULL
tested	NULL
ex	NULL
vivo	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
70:1	NULL
(	NULL
EM	NULL
)	NULL
,	NULL
30:1	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
15:1	NULL
(	NULL
RY	NULL
)	NULL
;	NULL
(	NULL
D	NULL
)	NULL
IMS3	NULL
CTL	NULL
line	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
10:1	NULL
(	NULL
EW	NULL
)	NULL
and	NULL
5:1	NULL
(	NULL
2	NULL
)	NULL
;	NULL
(	NULL
E	NULL
)	NULL
IM59	NULL
CTL	NULL
line	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
10:1	NULL
(	NULL
ER	NULL
)	NULL
and	NULL
5:1	NULL
(	NULL
2	NULL
)	NULL
;	NULL
and	NULL
(	NULL
F	NULL
)	NULL
IM63	NULL
CTL	NULL
line	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
%	NULL
specific	NULL
lysis	NULL
BZLFI	NULL
no	NULL
peptide	NULL
f	NULL
EBNA	NULL
325-333	NULL
190-197	NULL
\	NULL
154-166	NULL
autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
0.3-3	NULL
celly	NULL
well	NULL
using	NULL
the	NULL
conditions	NULL
outlined	NULL
above	NULL
.	NULL

All	NULL
primary	NULL
and	NULL
memory	NULL
CTL	NULL
clones	NULL
were	NULL
screened	NULL
for	NULL
CD4	NULL
and	NULL
CD8	NULL
expression	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
staining	NULL
using	NULL
the	NULL
CD4-specific	NULL
mAb	NULL
716	NULL
and	NULL
the	NULL
CD8-specific	NULL
mAb	NULL
707	NULL
(	NULL
Dako	NULL
,	NULL
High	NULL
Wycombe	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

Vaainia	NULL
R	NULL
ecombinants	NULL
and	NULL
Plasmid	NULL
Expression	NULL
V	NULL
etors	NULL
.	NULL

-	NULL
R	NULL
ecom-binant	NULL
vaccinia	NULL
viruses	NULL
expressing	NULL
the	NULL
EBV	NULL
immediate	NULL
early	NULL
proteins	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
,	NULL
and	NULL
the	NULL
early	NULL
proteins	NULL
BHRFI	NULL
and	NULL
BMLF1	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
34	NULL
)	NULL
;	NULL
note	NULL
that	NULL
the	NULL
vac-cinia-BMLF1	NULL
(	NULL
vacc-BMLF1	NULL
)	NULL
recombinant	NULL
expresses	NULL
a	NULL
truncated	NULL
form	NULL
of	NULL
BSLF2/BMLFI	NULL
protein	NULL
which	NULL
lacks	NULL
NH-terminal	NULL
sequences	NULL
provided	NULL
by	NULL
the	NULL
small	NULL
BSLF2	NULL
exon	NULL
.	NULL

Recombinants	NULL
expressing	NULL
the	NULL
early	NULL
proteins	NULL
BMRFI1	NULL
,	NULL
BHLFI	NULL
,	NULL
BALF2	NULL
,	NULL
and	NULL
BALF3	NULL
,	NULL
and	NULL
the	NULL
late	NULL
proteins	NULL
BCRFI1	NULL
and	NULL
BLLF1	NULL
,	NULL
were	NULL
generated	NULL
as	NULL
before	NULL
by	NULL
insertion	NULL
of	NULL
the	NULL
relevant	NULL
coding	NULL
sequence	NULL
into	NULL
the	NULL
vaccinia	NULL
thymidine	NULL
kinase	NULL
(	NULL
TK	NULL
)	NULL
gene	NULL
locus	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
vaccinia	NULL
P7.5	NULL
early-late	NULL
promoter	NULL
;	NULL
vace-TK~	NULL
is	NULL
a	NULL
control	NULL
recombinant	NULL
lacking	NULL
an	NULL
inserted	NULL
sequence	NULL
.	NULL

A	NULL
second	NULL
independently	NULL
constructed	NULL
vacc-BZLF1	NULL
recombinant	NULL
was	NULL
provided	NULL
by	NULL
Dr.	NULL
M.	NULL
Mackett	NULL
(	NULL
Paterson	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
Manchester	NULL
,	NULL
U.K.	NULL
)	NULL
.	NULL

All	NULL
vaccinia	NULL
recombinants	NULL
were	NULL
used	NULL
to	NULL
infect	NULL
target	NULL
cells	NULL
(	NULL
LCLs	NULL
,	NULL
fibroblasts	NULL
,	NULL
or	NULL
SV40-transformed	NULL
keratinocytes	NULL
)	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
of	NULL
10:1	NULL
followed	NULL
by	NULL
overnight	NULL
incubation	NULL
as	NULL
described	NULL
(	NULL
8	NULL
)	NULL
and	NULL
inclusion	NULL
in	NULL
a	NULL
standard	NULL
5-7	NULL
h	NULL
chromium	NULL
release	NULL
assay	NULL
.	NULL

BZLF1	NULL
was	NULL
also	NULL
expressed	NULL
in	NULL
SV40-transformed	NULL
keratinocyte	NULL
targets	NULL
by	NULL
transient	NULL
transfection	NULL
of	NULL
the	NULL
plasmid	NULL
vector	NULL
pSG5	NULL
(	NULL
Strat-agene	NULL
Ltd.	NULL
,	NULL
Cambridge	NULL
,	NULL
U.K.	NULL
)	NULL
carrying	NULL
a	NULL
BZLF1	NULL
gene	NULL
insert	NULL
(	NULL
pSGS-BZLF1	NULL
)	NULL
;	NULL
pSG5	NULL
itself	NULL
and	NULL
the	NULL
equivalent	NULL
pSG5-EBNA1	NULL
construct	NULL
served	NULL
as	NULL
controls	NULL
.	NULL

For	NULL
transfection	NULL
,	NULL
the	NULL
adherent	NULL
target	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
DME	NULL
and	NULL
then	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
2.5	NULL
ml	NULL
DME	NULL
containing	NULL
chloroquine	NULL
(	NULL
0.8	NULL
mM	NULL
)	NULL
,	NULL
DEAE	NULL
dextran	NULL
(	NULL
0.4	NULL
mg/	NULL
ml	NULL
)	NULL
,	NULL
and	NULL
10	NULL
jg	NULL
plasmid	NULL
DN	NULL
A	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
for	NULL
2	NULL
min	NULL
in	NULL
phosphate-	NULL
buffered	NULL
saline	NULL
containing	NULL
10	NULL
%	NULL
vol/	NULL
vol	NULL
DMSO	NULL
,	NULL
washed	NULL
twice	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
in	NULL
DME	NULL
+	NULL
10	NULL
%	NULL
vol/	NULL
vol	NULL
FCS	NULL
for	NULL
48	NULL
h	NULL
before	NULL
inclusion	NULL
in	NULL
a	NULL
standard	NULL
cytotoxicity	NULL
1607	NULL
Steven	NULL
et	NULL
al	NULL
.	NULL

autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
20:1	NULL
(	NULL
ER	NULL
)	NULL
and	NULL
10:1	NULL
(	NULL
2	NULL
)	NULL
.	NULL

assay	NULL
.	NULL

Expression	NULL
of	NULL
BZLF1	NULL
was	NULL
again	NULL
monitored	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
staining	NULL
with	NULL
mAb	NULL
BZ-1	NULL
.	NULL

Peptides	NULL
.	NULL

Peptides	NULL
were	NULL
synthesized	NULL
by	NULL
standard	NULL
fluorenyl-methoxycarbonyl	NULL
chemistry	NULL
(	NULL
Alta	NULL
Bioscience	NULL
,	NULL
University	NULL
of	NULL
Bir-mingham	NULL
)	NULL
,	NULL
dissolved	NULL
in	NULL
DMSO	NULL
,	NULL
and	NULL
their	NULL
concentrations	NULL
determined	NULL
by	NULL
biuret	NULL
assay	NULL
.	NULL

Target	NULL
cells	NULL
in	NULL
peptide	NULL
sensitization	NULL
assays	NULL
were	NULL
T	NULL
lymphoblasts	NULL
which	NULL
had	NULL
been	NULL
expanded	NULL
in	NULL
vitro	NULL
in	NULL
IL-2-enriched	NULL
medium	NULL
for	NULL
at	NULL
least	NULL
2	NULL
wk	NULL
after	NULL
initial	NULL
PHA	NULL
stimulation	NULL
;	NULL
such	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
appropriate	NULL
concentrations	NULL
of	NULL
peptide	NULL
(	NULL
or	NULL
with	NULL
dilutions	NULL
of	NULL
DMSO	NULL
solvent	NULL
as	NULL
a	NULL
control	NULL
)	NULL
for	NULL
1	NULL
h	NULL
before	NULL
inclusion	NULL
in	NULL
a	NULL
standard	NULL
cytotoxicity	NULL
assay	NULL
.	NULL

Where	NULL
large	NULL
numbers	NULL
of	NULL
overlapping	NULL
peptides	NULL
were	NULL
to	NULL
be	NULL
screened	NULL
for	NULL
epitope	NULL
location	NULL
,	NULL
CTL	NULL
recognition	NULL
was	NULL
monitored	NULL
using	NULL
a	NULL
direct	NULL
visual	NULL
as	NULL
say	NULL
of	NULL
T	NULL
cell-T	NULL
cell	NULL
killing	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Results	NULL
Recgnition	NULL
of	NULL
the	NULL
BZLFI	NULL
190-197	NULL
Peptide	NULL
Epitope	NULL
by	NULL
IM	NULL
Effectors	NULL
Ex	NULL
Vivo	NULL
.	NULL

The	NULL
initial	NULL
series	NULL
of	NULL
experiments	NULL
specifically	NULL
focused	NULL
on	NULL
IM	NULL
patients	NULL
with	NULL
an	NULL
HLA-B8	NULL
allele	NULL
to	NULL
check	NULL
for	NULL
recognition	NULL
of	NULL
the	NULL
reported	NULL
B8	NULL
epitope	NULL
peptide	NULL
BZLFI1	NULL
190-197	NULL
in	NULL
cytotoxicity	NULL
assays	NULL
using	NULL
IM	NULL
effectors	NULL
prepared	NULL
immediately	NULL
ex	NULL
vivo	NULL
.	NULL

Since	NULL
HLA-B8	NULL
is	NULL
also	NULL
known	NULL
to	NULL
present	NULL
two	NULL
immunodominant	NULL
epitopes	NULL
from	NULL
the	NULL
latent	NULL
cycle	NULL
protein	NULL
EBN	NULL
A3A	NULL
,	NULL
namely	NULL
158-166	NULL
and	NULL
325-333	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
these	NULL
peptides	NULL
were	NULL
included	NULL
as	NULL
reference	NULL
epitopes	NULL
in	NULL
the	NULL
same	NULL
assays	NULL
.	NULL

Cryopreserved	NULL
PBMCs	NULL
from	NULL
three	NULL
HLA-B8-positive	NULL
patients	NULL
,	NULL
IM53	NULL
,	NULL
IM59	NULL
and	NULL
IM63	NULL
,	NULL
were	NULL
thawed	NULL
into	NULL
IL-2-enriched	NULL
medium	NULL
and	NULL
used	NULL
immediately	NULL
as	NULL
effectors	NULL
in	NULL
7	NULL
h	NULL
chromium	NULL
release	NULL
assays	NULL
against	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
that	NULL
had	NULL
been	NULL
preexposed	NULL
to	NULL
the	NULL
relevant	NULL
epitope	NULL
peptides	NULL
The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A-C	NULL
.	NULL

There	NULL
was	NULL
clear	NULL
recognition	NULL
of	NULL
both	NULL
the	NULL
reference	NULL
latent	NULL
cy-	NULL
cle	NULL
EBN	NULL
A3A	NULL
epitopes	NULL
by	NULL
effectors	NULL
from	NULL
IM59	NULL
and	NULL
IM63	NULL
,	NULL
and	NULL
of	NULL
the	NULL
EBN	NULL
ABA	NULL
325-333	NULL
epitope	NULL
by	NULL
IM53	NULL
,	NULL
confirming	NULL
patterns	NULL
of	NULL
lysis	NULL
already	NULL
described	NULL
in	NULL
earlier	NULL
studies	NULL
with	NULL
cryopreserved	NULL
effectors	NULL
from	NULL
these	NULL
particular	NULL
patients	NULL
(	NULL
7	NULL
)	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
however	NULL
,	NULL
all	NULL
three	NULL
individuals	NULL
showed	NULL
even	NULL
stronger	NULL
recognition	NULL
of	NULL
targets	NULL
preloaded	NULL
with	NULL
the	NULL
BZLF1	NULL
190-197	NULL
peptide	NULL
.	NULL

Levels	NULL
of	NULL
lysis	NULL
clearly	NULL
above	NULL
background	NULL
were	NULL
detectable	NULL
at	NULL
effector/	NULL
target	NULL
ratios	NULL
from	NULL
80:1	NULL
down	NULL
to	NULL
as	NULL
low	NULL
as	NULL
15:1	NULL
;	NULL
note	NULL
that	NULL
primary	NULL
CTL	NULL
reactivities	NULL
against	NULL
immunodominant	NULL
latent	NULL
cycle	NULL
epitopes	NULL
frequently	NULL
became	NULL
undetectable	NULL
at	NULL
this	NULL
lower	NULL
ratio	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
Fig	NULL
.	NULL

1	NULL
C	NULL
and	NULL
reference	NULL
7	NULL
)	NULL
.	NULL

Subsequent	NULL
work	NULL
confirmed	NULL
that	NULL
this	NULL
recognition	NULL
of	NULL
the	NULL
BZLFI1	NULL
peptide	NULL
was	NULL
reproducible	NULL
in	NULL
repeat	NULL
assays	NULL
and	NULL
was	NULL
restricted	NULL
to	NULL
HLA-B8-positive	NULL
targets	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
Expansion	NULL
of	NULL
BZLFI	NULL
190-197-Readtive	NULL
CTLs	NULL
.	NULL

We	NULL
had	NULL
previously	NULL
established	NULL
autologous	NULL
LCL	NULL
stimulation	NULL
protocols	NULL
that	NULL
allowed	NULL
latent	NULL
antigen-specific	NULL
CTLs	NULL
within	NULL
the	NULL
IM	NULL
T	NULL
cell	NULL
population	NULL
to	NULL
be	NULL
expanded	NULL
in	NULL
vitro	NULL
either	NULL
as	NULL
short-term	NULL
bulk	NULL
polyclonal	NULL
lines	NULL
or	NULL
as	NULL
limiting	NULL
dilution	NULL
clones	NULL
.	NULL

Screening	NULL
LCL	NULL
cultures	NULL
that	NULL
had	NULL
been	NULL
established	NULL
by	NULL
spontaneous	NULL
in	NULL
vitro	NULL
transformation	NULL
from	NULL
the	NULL
above	NULL
IM	NULL
patients	NULL
identified	NULL
up	NULL
to	NULL
5	NULL
%	NULL
cells	NULL
expressing	NULL
the	NULL
BZLFI1	NULL
immediate	NULL
early	NULL
protein	NULL
and	NULL
up	NULL
to	NULL
2	NULL
%	NULL
cells	NULL
positive	NULL
for	NULL
the	NULL
late	NULL
lytic	NULL
cycle	NULL
marker	NULL
virus	NULL
capsid	NULL
antigen	NULL
.	NULL

Such	NULL
autologous	NULL
LCLs	NULL
were	NULL
therefore	NULL
used	NULL
as	NULL
a	NULL
source	NULL
of	NULL
EBV	NULL
lytic	NULL
antigen-positive	NULL
stimulators	NULL
in	NULL
an	NULL
effort	NULL
to	NULL
expand	NULL
the	NULL
above	NULL
BZLFI	NULL
epitope-specific	NULL
CTLs	NULL
in	NULL
vitro	NULL
.	NULL

In	NULL
the	NULL
first	NULL
instance	NULL
,	NULL
thawed	NULL
IM	NULL
effectors	NULL
were	NULL
expanded	NULL
as	NULL
short-term	NULL
bulk	NULL
cultures	NULL
in	NULL
IL-2-enriched	NULL
medium	NULL
with	NULL
immediate	NULL
autologous	NULL
LCL	NULL
stimulation	NULL
,	NULL
and	NULL
assayed	NULL
for	NULL
cytotoxic	NULL
activity	NULL
against	NULL
peptide-loaded	NULL
target	NULL
cells	NULL
after	NULL
two	NULL
weeks	NULL
.	NULL

The	NULL
results	NULL
thus	NULL
obtained	NULL
from	NULL
the	NULL
same	NULL
three	NULL
indi-viduals	NULL
,	NULL
IM53	NULL
,	NULL
IM59	NULL
,	NULL
and	NULL
IM63	NULL
,	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
D-F	NULL
.	NULL

In	NULL
each	NULL
case	NULL
,	NULL
effectors	NULL
specific	NULL
for	NULL
the	NULL
BZLF1	NULL
190-197	NULL
epitope	NULL
were	NULL
detectable	NULL
in	NULL
the	NULL
in	NULL
vitro-expanded	NULL
populations	NULL
,	NULL
here	NULL
tested	NULL
at	NULL
effector/	NULL
target	NULL
ratios	NULL
between	NULL
20:1	NULL
and	NULL
5:1	NULL
.	NULL

However	NULL
,	NULL
the	NULL
overall	NULL
pattern	NULL
of	NULL
results	NULL
indicates	NULL
that	NULL
these	NULL
effectors	NULL
had	NULL
not	NULL
been	NULL
expanded	NULL
as	NULL
efficiently	NULL
as	NULL
the	NULL
latent	NULL
cycle-specific	NULL
CTLs	NULL
.	NULL

This	NULL
is	NULL
particularly	NULL
apparent	NULL
for	NULL
IM53	NULL
,	NULL
where	NULL
in	NULL
vitro	NULL
expansion	NULL
had	NULL
maintained	NULL
the	NULL
original	NULL
EBNA3A	NULL
325-333	NULL
reactivity	NULL
and	NULL
now	NULL
also	NULL
revealed	NULL
an	NULL
EBNA3A	NULL
158-166	NULL
reactivity	NULL
which	NULL
had	NULL
been	NULL
below	NULL
the	NULL
level	NULL
of	NULL
detection	NULL
in	NULL
ex	NULL
vivo	NULL
assays	NULL
;	NULL
by	NULL
contrast	NULL
,	NULL
the	NULL
BZLFI	NULL
190-197	NULL
reactivity	NULL
was	NULL
now	NULL
comparatively	NULL
weak	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Our	NULL
recent	NULL
work	NULL
studying	NULL
latent	NULL
cycle	NULL
specificities	NULL
within	NULL
IM	NULL
T	NULL
cell	NULL
preparations	NULL
had	NULL
indicated	NULL
that	NULL
low	NULL
abundance	NULL
CTLs	NULL
could	NULL
be	NULL
separated	NULL
from	NULL
immunodominant	NULL
components	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
in	NULL
IL-2-conditioned	NULL
medium	NULL
on	NULL
a	NULL
combination	NULL
of	NULL
autologous	NULL
LCL	NULL
cells	NULL
and	NULL
pooled	NULL
allogeneic	NULL
PBL	NULL
feeders	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
adopted	NULL
this	NULL
same	NULL
approach	NULL
in	NULL
an	NULL
effort	NULL
to	NULL
isolate	NULL
CTLs	NULL
specific	NULL
for	NULL
the	NULL
BZLF1	NULL
190-197	NULL
epitope	NULL
away	NULL
from	NULL
the	NULL
co-resident	NULL
latent	NULL
cycle-specific	NULL
reactivities	NULL
.	NULL

Cryopreserved	NULL
ex	NULL
vivo	NULL
ef-fector	NULL
populations	NULL
from	NULL
reference	NULL
donors	NULL
IM53	NULL
and	NULL
IM59	NULL
were	NULL
seeded	NULL
at	NULL
30-100	NULL
celly	NULL
well	NULL
,	NULL
and	NULL
all	NULL
wells	NULL
showing	NULL
successful	NULL
T	NULL
cell	NULL
outgrowth	NULL
were	NULL
screened	NULL
for	NULL
epitope-spe-	NULL
1608	NULL
cific	NULL
reactivities	NULL
These	NULL
experiments	NULL
showed	NULL
that	NULL
30-60	NULL
%	NULL
of	NULL
growing	NULL
wells	NULL
contained	NULL
BZLF1	NULL
epitope-specific	NULL
CTLs	NULL
;	NULL
this	NULL
was	NULL
at	NULL
least	NULL
as	NULL
high	NULL
as	NULL
the	NULL
proportion	NULL
of	NULL
wells	NULL
with	NULL
EBN	NULL
A3A	NULL
reactivity	NULL
in	NULL
each	NULL
experiment	NULL
(	NULL
assayed	NULL
using	NULL
peptide	NULL
325-333	NULL
for	NULL
IM53	NULL
and	NULL
peptide	NULL
158-166	NULL
for	NULL
IM59	NULL
)	NULL
and	NULL
in	NULL
many	NULL
instances	NULL
,	NULL
the	NULL
BZLFI	NULL
and	NULL
EBN	NULL
A3A	NULL
epitopes	NULL
reactivities	NULL
were	NULL
now	NULL
present	NULL
in	NULL
separate	NULL
wells	NULL
.	NULL

In	NULL
further	NULL
assays	NULL
of	NULL
cloning	NULL
strategies	NULL
using	NULL
ex	NULL
vivo	NULL
effectors	NULL
from	NULL
IM63	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
BZLF1	NULL
epitope-specific	NULL
CTLs	NULL
(	NULL
and	NULL
other	NULL
lytic	NULL
cycle	NULL
reactivities	NULL
,	NULL
see	NULL
later	NULL
)	NULL
could	NULL
be	NULL
expanded	NULL
almost	NULL
as	NULL
efficiently	NULL
with	NULL
the	NULL
CD3-specific	NULL
mAb	NULL
OKT	NULL
3	NULL
as	NULL
a	NULL
stimulus	NULL
as	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
.	NULL

In	NULL
subsequent	NULL
experiments	NULL
,	NULL
therefore	NULL
,	NULL
we	NULL
used	NULL
the	NULL
two	NULL
methods	NULL
of	NULL
stimulation	NULL
in	NULL
paral-lel	NULL
.	NULL

Both	NULL
yielded	NULL
limiting	NULL
dilution	NULL
clones	NULL
which	NULL
could	NULL
be	NULL
maintained	NULL
for	NULL
several	NULL
weeks	NULL
in	NULL
IL-2-conditioned	NULL
medium	NULL
with	NULL
appropriate	NULL
stimulation	NULL
and	NULL
which	NULL
could	NULL
be	NULL
sub-cloned	NULL
,	NULL
if	NULL
necessary	NULL
,	NULL
to	NULL
check	NULL
specificity	NULL
.	NULL

Confinmation	NULL
of	NULL
BZLFI	NULL
Antigen	NULL
Spedfiaty	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
A	NULL
shows	NULL
data	NULL
from	NULL
a	NULL
representative	NULL
BZLFI	NULL
epitope-specific	NULL
clone	NULL
,	NULL
IM63	NULL
c34	NULL
,	NULL
obtained	NULL
as	NULL
described	NULL
by	NULL
limiting	NULL
dilution	NULL
culture	NULL
of	NULL
IM63	NULL
PBMCs	NULL
ex	NULL
vivo	NULL
.	NULL

The	NULL
results	NULL
illustrate	NULL
an	NULL
unusual	NULL
feature	NULL
of	NULL
the	NULL
BZLFI1	NULL
190-197	NULL
epitope-specific	NULL
response	NULL
that	NULL
we	NULL
consistently	NULL
observed	NULL
with	NULL
cloned	NULL
effectors	NULL
from	NULL
IM53	NULL
,	NULL
IM59	NULL
,	NULL
and	NULL
IM63	NULL
.	NULL

These	NULL
CTLs	NULL
efficiently	NULL
recognized	NULL
autologous	NULL
and	NULL
HLA-B8-matched	NULL
target	NULL
cells	NULL
when	NULL
they	NULL
were	NULL
preloaded	NULL
with	NULL
the	NULL
relevant	NULL
epitope	NULL
peptide	NULL
,	NULL
but	NULL
not	NULL
when	NULL
they	NULL
were	NULL
infected	NULL
with	NULL
a	NULL
recombinant	NULL
vaccinia	NULL
vector	NULL
expressing	NULL
the	NULL
full	NULL
length	NULL
BZLF1	NULL
protein	NULL
.	NULL

We	NULL
made	NULL
the	NULL
same	NULL
observation	NULL
using	NULL
two	NULL
independently	NULL
constructed	NULL
vacc-BZLFI1	NULL
recombinants	NULL
and	NULL
three	NULL
different	NULL
types	NULL
of	NULL
target	NULL
cells	NULL
(	NULL
LCLs	NULL
,	NULL
fibroblasts	NULL
,	NULL
keratinocytes	NULL
)	NULL
in	NULL
assays	NULL
where	NULL
efficient	NULL
expression	NULL
of	NULL
BZLFI1	NULL
in	NULL
the	NULL
vaccinia-infected	NULL
targets	NULL
was	NULL
confirmed	NULL
by	NULL
immunofluorescence	NULL
stain-ing	NULL
.	NULL

To	NULL
check	NULL
whether	NULL
BZLF1	NULL
could	NULL
ever	NULL
be	NULL
processed	NULL
to	NULL
generate	NULL
the	NULL
190-197	NULL
epitope	NULL
,	NULL
the	NULL
experiments	NULL
were	NULL
extended	NULL
to	NULL
include	NULL
a	NULL
B8-positive	NULL
keratinocyte	NULL
line	NULL
in	NULL
which	NULL
BZLF1	NULL
expression	NULL
could	NULL
be	NULL
achieved	NULL
in	NULL
up	NULL
to	NULL
40	NULL
%	NULL
cells	NULL
by	NULL
transient	NULL
transfection	NULL
with	NULL
a	NULL
plasmid	NULL
vector	NULL
.	NULL

CTL	NULL
clones	NULL
such	NULL
as	NULL
IM63	NULL
c34	NULL
now	NULL
showed	NULL
clear	NULL
recognition	NULL
not	NULL
only	NULL
of	NULL
the	NULL
190-197	NULL
peptide	NULL
,	NULL
but	NULL
also	NULL
of	NULL
the	NULL
BZLF1-positive	NULL
targets	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

We	NULL
then	NULL
went	NULL
back	NULL
to	NULL
cryopreserved	NULL
ex	NULL
vivo	NULL
effectors	NULL
from	NULL
IM63	NULL
and	NULL
also	NULL
from	NULL
IM59	NULL
,	NULL
to	NULL
carry	NULL
out	NULL
this	NULL
same	NULL
type	NULL
of	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
these	NULL
primary	NULL
cells	NULL
were	NULL
also	NULL
found	NULL
to	NULL
recognize	NULL
target	NULL
cells	NULL
expressing	NULL
BZLF1	NULL
from	NULL
the	NULL
transiently	NULL
transfected	NULL
plasmid	NULL
vector	NULL
,	NULL
but	NULL
not	NULL
targets	NULL
infected	NULL
with	NULL
the	NULL
vacc-BZLFI	NULL
recombinant	NULL
.	NULL

We	NULL
infer	NULL
that	NULL
the	NULL
above	NULL
effectors	NULL
are	NULL
indeed	NULL
reactive	NULL
to	NULL
the	NULL
immediate	NULL
early	NULL
protein	NULL
BZLF1	NULL
and	NULL
that	NULL
processing	NULL
of	NULL
the	NULL
190-197	NULL
epitope	NULL
is	NULL
somehow	NULL
impaired	NULL
in	NULL
vaccinia-	NULL
infected	NULL
cells	NULL
.	NULL

Identification	NULL
of	NULL
Additional	NULL
Subdominant	NULL
Readivities	NULL
to	NULL
Early	NULL
Lytic	NULL
Proteins	NULL
A	NULL
longside	NULL
the	NULL
BZLFI	NULL
Response	NULL
.	NULL

Having	NULL
established	NULL
limiting	NULL
dilution	NULL
conditions	NULL
capable	NULL
of	NULL
expanding	NULL
the	NULL
BZLF1-specific	NULL
T	NULL
cells	NULL
from	NULL
B8-positive	NULL
IM	NULL
patients	NULL
,	NULL
the	NULL
work	NULL
was	NULL
extended	NULL
to	NULL
look	NULL
for	NULL
CTL	NULL
reactivities	NULL
to	NULL
other	NULL
lytic	NULL
cycle	NULL
antigens	NULL
.	NULL

It	NULL
seemed	NULL
to	NULL
us	NULL
most	NULL
unlikely	NULL
that	NULL
the	NULL
processing	NULL
and	NULL
presentation	NULL
of	NULL
lytic	NULL
cycle	NULL
epitopes	NULL
would	NULL
be	NULL
generally	NULL
impaired	NULL
in	NULL
the	NULL
vaccinia	NULL
system	NULL
and	NULL
we	NULL
therefore	NULL
CTL	NULL
Responses	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Lytic	NULL
Cycle	NULL
Antigens	NULL
A	NULL
__	NULL
IM63	NULL
primary	NULL
c34	NULL
2	NULL
3	NULL
9	NULL
215	NULL
2	NULL
a	NULL
j	NULL
_	NULL
no	NULL
-	NULL
BZLFI	NULL
'	NULL
vacu-	NULL
'	NULL
vacee	NULL
-	NULL
pSGS	NULL
-	NULL
pSGS-peptlde	NULL
190-	NULL
197	NULL
TK-	NULL
-	NULL
BZLFI	NULL
BZLFI	NULL
IL	NULL
|	NULL
autologous	NULL
PHA	NULL
__	NULL
B8-matched	NULL
BS8-matched	NULL
blasts	NULL
+	NULL
peptide	NULL
keratinocytes	NULL
keratinocytes	NULL
B	NULL
_	NULL
IM63	NULL
ex	NULL
vivo	NULL
effectors	NULL
30	NULL
g	NULL
9	NULL
2	NULL
15	NULL
8	NULL
5	NULL
s	NULL
o	NULL
|	NULL
:	NULL
no	NULL
__	NULL
BZLFI	NULL
pSGS5	NULL
pSGS-peptide	NULL
190-197	NULL
BZLFI	NULL
B8-matched	NULL
keratinocytes	NULL
autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
C	NULL
__	NULL
IMS9	NULL
ex	NULL
vivo	NULL
effectors	NULL
20	NULL
2	NULL
2	NULL
5	NULL
A	NULL
3	NULL
P	NULL
3	NULL
10	NULL
f	NULL
;	NULL
:	NULL
A	NULL
§	NULL
f	NULL
'	NULL
l	NULL
.	NULL

_E	NULL
o	NULL
2	NULL
no	NULL
-	NULL
BZLFI	NULL
-	NULL
vacee	NULL
-	NULL
pSGS	NULL
pSGS-peptide	NULL
190-197	NULL
TK-	NULL
-	NULL
BZLFI	NULL
BZLFI	NULL
I	NULL
-II	NULL
1	NULL
I	NULL
--	NULL
--	NULL
autologous	NULL
PHA	NULL
B8-matched	NULL
B	NULL
&	NULL
-matched	NULL
blasts	NULL
+	NULL
peptide	NULL
fibroblasts	NULL
keratinocytes	NULL
Figure	NULL
2	NULL
.	NULL

Screening	NULL
of	NULL
BZLF1	NULL
190-197	NULL
epitope-specific	NULL
effectors	NULL
for	NULL
recognition	NULL
of	NULL
targets	NULL
expressing	NULL
the	NULL
BZLFI	NULL
protein	NULL
.	NULL

Assays	NULL
were	NULL
conducted	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
pretreated	NULL
with	NULL
the	NULL
BZLFI1	NULL
190-197	NULL
peptide	NULL
at	NULL
2	NULL
ug/ml	NULL
or	NULL
with	NULL
an	NULL
equivalent	NULL
concentration	NULL
of	NULL
DMSO	NULL
alone	NULL
(	NULL
``	NULL
no	NULL
peptide	NULL
``	NULL
control	NULL
)	NULL
,	NULL
and	NULL
on	NULL
HLA-B8-matched	NULL
keratinocyte	NULL
or	NULL
fibroblast	NULL
targets	NULL
infected	NULL
with	NULL
vace-BZLFI1	NULL
or	NULL
with	NULL
vacc-TK~	NULL
as	NULL
a	NULL
con-trol	NULL
,	NULL
or	NULL
transiently	NULL
transfected	NULL
with	NULL
pSG5-BZLF1	NULL
or	NULL
with	NULL
pSG5	NULL
as	NULL
a	NULL
control	NULL
.	NULL

R	NULL
esults	NULL
are	NULL
expressed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
for	NULL
(	NULL
A	NULL
)	NULL
IM63	NULL
primary	NULL
clone	NULL
34	NULL
established	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
of	NULL
IM63	NULL
effectors	NULL
ex	NULL
vivo	NULL
and	NULL
tested	NULL
at	NULL
a	NULL
E/T	NULL
ratio	NULL
of	NULL
5:1	NULL
,	NULL
and	NULL
for	NULL
(	NULL
B	NULL
)	NULL
IM63	NULL
ex	NULL
vivo	NULL
effectors	NULL
and	NULL
(	NULL
C	NULL
)	NULL
IM59	NULL
ex	NULL
vivo	NULL
effectors	NULL
,	NULL
both	NULL
tested	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
80:1	NULL
(	NULL
BB	NULL
)	NULL
and	NULL
40:1	NULL
(	NULL
2	NULL
)	NULL
.	NULL

elected	NULL
to	NULL
screen	NULL
IM-derived	NULL
limiting	NULL
dilution	NULL
cultures	NULL
on	NULL
autologous	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
one	NULL
of	NULL
a	NULL
panel	NULL
of	NULL
vaccinia	NULL
recombinants	NULL
expressing	NULL
the	NULL
immediate	NULL
early	NULL
proteins	NULL
and	NULL
BRLF1I	NULL
,	NULL
the	NULL
early	NULL
proteins	NULL
BMLF1	NULL
,	NULL
BMRFI	NULL
,	NULL
BHLFI	NULL
,	NULL
BHRFI	NULL
,	NULL
BALF2	NULL
,	NULL
and	NULL
BALFS5	NULL
,	NULL
and	NULL
the	NULL
late	NULL
proteins	NULL
BCRFI	NULL
and	NULL
BLLFI	NULL
.	NULL

1609	NULL
Steven	NULL
et	NULL
al	NULL
.	NULL

z	NULL
»	NULL
IM63	NULL
c70	NULL
40	NULL
%	NULL
specific	NULL
lysis	NULL
u	NULL
&	NULL
Autologous	NULL
Al	NULL
-	NULL
A2Z0S	NULL
BS.C7	NULL
-	NULL
B49	NULL
-	NULL
CG	NULL
|	NULL
match	NULL
_	NULL
match	NULL
_	NULL
match	NULL
_	NULL
match	NULL
_	NULL
match	NULL
HLA	NULL
class	NULL
I~matched	NULL
LCL	NULL
+	NULL
vace-BRLFI	NULL
B	NULL
-	NULL
IM63	NULL
c9.1	NULL
50	NULL
3	NULL
2s	NULL
&	NULL
$	NULL
0	NULL
a	NULL
-K	NULL
__	NULL
,	NULL
t	NULL
autologous	NULL
_	NULL
Al	NULL
BS	NULL
B49	NULL
C6	NULL
match	NULL
match	NULL
match	NULL
match	NULL
HLA	NULL
class	NULL
I-matched	NULL
LCL	NULL
+	NULL
vace-BMRFI	NULL
C	NULL
_	NULL
IM63	NULL
c9.1	NULL
50	NULL
7	NULL
269-276	NULL
-	NULL
RSGITAVV	NULL
268-276	NULL
YRSGHIAVV	NULL
267-275	NULL
FYRSGIIAV	NULL
267-276	NULL
FYRSGINAVV	NULL
%	NULL
specific	NULL
lysis	NULL
bo	NULL
tn	NULL
V	NULL
268-277	NULL
YRSGIIAVVA	NULL
10-2	NULL
104	NULL
1019	NULL
10	NULL
'	NULL
9	NULL
s	NULL
10-7	NULL
106	NULL
105	NULL
peptide	NULL
concentration	NULL
(	NULL
M	NULL
)	NULL
Figure	NULL
3	NULL
.	NULL

Cytotoxicity	NULL
testing	NULL
of	NULL
CTL	NULL
clones	NULL
established	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
of	NULL
IM63	NULL
effectors	NULL
ex	NULL
vivo	NULL
.	NULL

Analysis	NULL
of	NULL
(	NULL
A	NULL
)	NULL
IM63	NULL
primary	NULL
clone	NULL
70	NULL
and	NULL
(	NULL
B	NULL
)	NULL
IM63	NULL
primary	NULL
clone	NULL
9.1	NULL
for	NULL
HLA	NULL
restriction	NULL
by	NULL
screening	NULL
on	NULL
the	NULL
autologous	NULL
LCL	NULL
and	NULL
on	NULL
a	NULL
panel	NULL
of	NULL
allogeneic	NULL
LCLs	NULL
infected	NULL
with	NULL
(	NULL
A	NULL
)	NULL
vace-BMLFI1	NULL
and	NULL
(	NULL
B	NULL
)	NULL
vacc-BMRFI	NULL
.	NULL

For	NULL
each	NULL
allogeneic	NULL
LCL	NULL
target	NULL
,	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
alleles	NULL
shared	NULL
with	NULL
IM63	NULL
are	NULL
indicated	NULL
;	NULL
note	NULL
that	NULL
in	NULL
(	NULL
A	NULL
)	NULL
the	NULL
Al-	NULL
and	NULL
the	NULL
C6-matched	NULL
targets	NULL
also	NULL
express	NULL
HLA-A2.01	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
A2.05-restricted	NULL
CTL	NULL
clone	NULL
can	NULL
not	NULL
use	NULL
A2.01	NULL
as	NULL
a	NULL
restriction	NULL
element	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Analysis	NULL
of	NULL
IM63	NULL
primary	NULL
clone	NULL
9.1	NULL
for	NULL
peptide	NULL
epitope	NULL
specificity	NULL
by	NULL
screening	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
pretreated	NULL
with	NULL
the	NULL
following	NULL
BMRFI	NULL
peptides	NULL
at	NULL
10	NULL
%	NULL
to	NULL
10~	NULL
``	NULL
M	NULL
concentrations	NULL
;	NULL
BMRFI	NULL
267-276	NULL
(	NULL
@	NULL
)	NULL
,	NULL
267-275	NULL
(	NULL
V	NULL
)	NULL
,	NULL
268-277	NULL
(	NULL
&	NULL
)	NULL
,	NULL
268-276	NULL
(	NULL
¥	NULL
)	NULL
,	NULL
and	NULL
269-276	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
all	NULL
assays	NULL
were	NULL
conducted	NULL
at	NULL
an	NULL
E/T	NULL
ratio	NULL
of	NULL
5:1	NULL
.	NULL

Two	NULL
of	NULL
the	NULL
original	NULL
patients	NULL
,	NULL
IM63	NULL
and	NULL
IM53	NULL
,	NULL
were	NULL
studied	NULL
in	NULL
this	NULL
way	NULL
and	NULL
both	NULL
revealed	NULL
additional	NULL
lytic	NULL
antigen-specific	NULL
CTL	NULL
reactivities	NULL
that	NULL
were	NULL
less	NULL
abundant	NULL
than	NULL
the	NULL
HLA-B8-restricted	NULL
BZLF1	NULL
response	NULL
,	NULL
but	NULL
were	NULL
nevertheless	NULL
detectable	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
.	NULL

For	NULL
IM63	NULL
,	NULL
there	NULL
were	NULL
two	NULL
such	NULL
reactivities	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

One	NULL
,	NULL
exemplified	NULL
by	NULL
IM63	NULL
c70	NULL
,	NULL
showed	NULL
specific	NULL
recognition	NULL
of	NULL
BRLFI	NULL
in	NULL
recombinant	NULL
vaccinia	NULL
assays	NULL
and	NULL
,	NULL
when	NULL
tested	NULL
on	NULL
a	NULL
range	NULL
of	NULL
vace-BRLFl-infected	NULL
allogeneic	NULL
LCLs	NULL
each	NULL
sharing	NULL
a	NULL
single	NULL
HLA	NULL
allele	NULL
with	NULL
IM63	NULL
(	NULL
HLA-A1	NULL
,	NULL
A2.05	NULL
,	NULL
B7	NULL
,	NULL
B49	NULL
,	NULL
C6	NULL
,	NULL
C7	NULL
)	NULL
,	NULL
was	NULL
found	NULL
to	NULL
be	NULL
restricted	NULL
through	NULL
HLA-A2.05	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
)	NULL
.	NULL

The	NULL
other	NULL
reactivity	NULL
,	NULL
exemplified	NULL
by	NULL
IM63	NULL
c9.1	NULL
,	NULL
was	NULL
directed	NULL
against	NULL
BMRFI1	NULL
and	NULL
was	NULL
restricted	NULL
through	NULL
HLA-C6	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

These	NULL
BMRFI1-specific	NULL
effectors	NULL
were	NULL
then	NULL
screened	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
preexposed	NULL
to	NULL
individual	NULL
peptides	NULL
(	NULL
15	NULL
mer	NULL
overlapping	NULL
by	NULL
10	NULL
)	NULL
from	NULL
a	NULL
panel	NULL
which	NULL
covered	NULL
the	NULL
entire	NULL
primary	NULL
sequence	NULL
of	NULL
the	NULL
BMRFI	NULL
protein	NULL
.	NULL

Using	NULL
a	NULL
visual	NULL
assay	NULL
of	NULL
T	NULL
cell-T	NULL
cell	NULL
kill-ing	NULL
,	NULL
this	NULL
screening	NULL
showed	NULL
recognition	NULL
of	NULL
a	NULL
single	NULL
peptide	NULL
BMRFI	NULL
266-280	NULL
.	NULL

Subsequent	NULL
titration	NULL
of	NULL
9-	NULL
and	NULL
10-mer	NULL
peptides	NULL
within	NULL
this	NULL
region	NULL
in	NULL
standard	NULL
chromium	NULL
release	NULL
assays	NULL
identified	NULL
the	NULL
sequence	NULL
YRSGIIAVV	NULL
(	NULL
BMRFI	NULL
268-276	NULL
)	NULL
as	NULL
the	NULL
minimal	NULL
HLA-C	NULL
epitope	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
C	NULL
)	NULL
;	NULL
this	NULL
accords	NULL
well	NULL
to	NULL
the	NULL
consensus	NULL
sequence	NULL
proposed	NULL
for	NULL
C6-binding	NULL
peptides	NULL
based	NULL
on	NULL
peptide	NULL
elution	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
subsequent	NULL
ex	NULL
vivo	NULL
assays	NULL
on	NULL
cryopreserved	NULL
effectors	NULL
from	NULL
IM63	NULL
did	NULL
not	NULL
show	NULL
detectable	NULL
reactivity	NULL
against	NULL
BMRFI	NULL
268-276	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
again	NULL
indicating	NULL
that	NULL
this	NULL
BMRFI	NULL
reactivity	NULL
was	NULL
subdominant	NULL
compared	NULL
to	NULL
the	NULL
BZLFI	NULL
response	NULL
.	NULL

Extension	NULL
of	NULL
the	NULL
work	NULL
to	NULL
the	NULL
other	NULL
patient	NULL
,	NULL
IM53	NULL
,	NULL
revealed	NULL
another	NULL
novel	NULL
lytic	NULL
antigen-specific	NULL
reactivity	NULL
which	NULL
could	NULL
be	NULL
detected	NULL
at	NULL
the	NULL
clonal	NULL
level	NULL
.	NULL

A	NULL
single	NULL
clone	NULL
from	NULL
IM53	NULL
consistently	NULL
recognized	NULL
vacc-	NULL
BMLF1-infected	NULL
cells	NULL
;	NULL
assays	NULL
on	NULL
allogeneic	NULL
LCLs	NULL
matched	NULL
through	NULL
single	NULL
HLA	NULL
alleles	NULL
with	NULL
IM53-identified	NULL
HLA-B18	NULL
as	NULL
the	NULL
restriction	NULL
ele-ment	NULL
,	NULL
and	NULL
peptide	NULL
sensitization	NULL
assays	NULL
identified	NULL
the	NULL
minimal	NULL
epitope	NULL
as	NULL
BMLFI	NULL
residues	NULL
397-405	NULL
,	NULL
DEVEFLGHY	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
Immunodominant	NULL
HLA-A	NULL
2.01-restnaed	NULL
Epitope	NULL
in	NULL
the	NULL
Early	NULL
Lytic	NULL
Protein	NULL
BMLFI	NULL
.	NULL

_	NULL
We	NULL
subsequently	NULL
went	NULL
on	NULL
to	NULL
test	NULL
a	NULL
number	NULL
of	NULL
IM	NULL
patients	NULL
who	NULL
did	NULL
not	NULL
have	NULL
the	NULL
HLA-B8	NULL
allele	NULL
to	NULL
look	NULL
for	NULL
evidence	NULL
of	NULL
other	NULL
immunodominant	NULL
reactivities	NULL
to	NULL
lytic	NULL
cycle	NULL
antigens	NULL
.	NULL

Analysis	NULL
of	NULL
IM69	NULL
(	NULL
HLA-A2.01	NULL
,	NULL
A32	NULL
,	NULL
B7	NULL
,	NULL
B63	NULL
)	NULL
,	NULL
whose	NULL
predominant	NULL
latent	NULL
antigen-specific	NULL
response	NULL
had	NULL
earlier	NULL
been	NULL
mapped	NULL
to	NULL
the	NULL
HLA-B7-restricted	NULL
epitope	NULL
EBN	NULL
A3A	NULL
379-387	NULL
(	NULL
7	NULL
)	NULL
,	NULL
yielded	NULL
a	NULL
number	NULL
of	NULL
CTL	NULL
clones	NULL
which	NULL
strongly	NULL
recognized	NULL
the	NULL
vacc-BMLFl-infected	NULL
autologous	NULL
LCL	NULL
in	NULL
the	NULL
original	NULL
screening	NULL
assays	NULL
and	NULL
which	NULL
proved	NULL
to	NULL
be	NULL
HLA-A2.01	NULL
restricted	NULL
on	NULL
extension	NULL
of	NULL
the	NULL
work	NULL
to	NULL
vace-	NULL
BMLF1-infected	NULL
allogeneic	NULL
targets	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
A	NULL
)	NULL
.	NULL

Peptide	NULL
sensitization	NULL
assays	NULL
with	NULL
the	NULL
BMLF1	NULL
panel	NULL
of	NULL
synthetic	NULL
peptides	NULL
first	NULL
mapped	NULL
recognition	NULL
to	NULL
the	NULL
15-mer	NULL
BMLF1	NULL
276-290	NULL
and	NULL
subsequent	NULL
assays	NULL
identified	NULL
the	NULL
minimal	NULL
epitope	NULL
as	NULL
BMLFI1	NULL
residues	NULL
280-288	NULL
,	NULL
GLCTLVAML	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
;	NULL
again	NULL
,	NULL
this	NULL
accords	NULL
well	NULL
to	NULL
the	NULL
consensus	NULL
sequence	NULL
for	NULL
A2.01-binding	NULL
peptides	NULL
(	NULL
39	NULL
)	NULL
.	NULL

In	NULL
view	NULL
of	NULL
the	NULL
number	NULL
of	NULL
clones	NULL
from	NULL
IM69	NULL
which	NULL
recognized	NULL
the	NULL
epitope	NULL
,	NULL
we	NULL
tested	NULL
cryopreserved	NULL
effectors	NULL
from	NULL
this	NULL
individual	NULL
and	NULL
from	NULL
a	NULL
second	NULL
HLA-A2.01	NULL
,	NULL
B7-positive	NULL
patient	NULL
IM61	NULL
for	NULL
evidence	NULL
of	NULL
BMLFI	NULL
280-288-specific	NULL
lysis	NULL
in	NULL
ex	NULL
vivo	NULL
assays	NULL
.	NULL

The	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
the	NULL
response	NULL
to	NULL
this	NULL
A2.01-restricted	NULL
BMLFI1	NULL
epitope	NULL
was	NULL
easily	NULL
detectable	NULL
in	NULL
the	NULL
primary	NULL
CTL	NULL
1610	NULL
A	NULL
.	NULL

_	NULL
IM69	NULL
c62	NULL
80	NULL
2	NULL
,	NULL
2	NULL
2	NULL
40-19	NULL
fad	NULL
a	NULL
O	NULL
I	NULL
I	NULL
I	NULL
-	NULL
I	NULL
autologous	NULL
-	NULL
A32	NULL
A2.01	NULL
B7	NULL
no	NULL
match	NULL
match	NULL
match	NULL
match	NULL
HLA	NULL
class	NULL
I-maiched	NULL
LCL	NULL
+	NULL
vace-BMLFI	NULL
B	NULL
.	NULL

-	NULL
IM69	NULL
c62	NULL
60	NULL
279-288	NULL
AGLCTLVAML	NULL
280-288	NULL
-	NULL
GLCTLVAML	NULL
%	NULL
specific	NULL
lysis	NULL
t	NULL
&	NULL
280-289	NULL
-	NULL
GLCTLVAMLE	NULL
1000	NULL
102	NULL
108	NULL
107	NULL
106	NULL
105	NULL
peptide	NULL
concentration	NULL
(	NULL
M	NULL
)	NULL
Figure	NULL
4	NULL
.	NULL

-	NULL
Cytotoxicity	NULL
testing	NULL
of	NULL
IM69	NULL
primary	NULL
clone	NULL
62	NULL
established	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
of	NULL
IM69	NULL
effectors	NULL
ex	NULL
vivo	NULL
.	NULL

(	NULL
A4	NULL
)	NULL
Analysis	NULL
of	NULL
HLA	NULL
restriction	NULL
by	NULL
screening	NULL
on	NULL
the	NULL
vace-BMLFI-infected	NULL
autologous	NULL
LCL	NULL
and	NULL
on	NULL
a	NULL
panel	NULL
of	NULL
vace-BMLF1-infected	NULL
allogeneic	NULL
LCL	NULL
s	NULL
sharing	NULL
individual	NULL
HLA	NULL
class	NULL
I	NULL
alleles	NULL
with	NULL
IM69	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Analysis	NULL
of	NULL
peptide	NULL
epitope	NULL
specificity	NULL
by	NULL
screening	NULL
on	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
pretreated	NULL
with	NULL
the	NULL
following	NULL
BMLF1	NULL
peptides	NULL
at	NULL
10~	NULL
to	NULL
10~	NULL
!	NULL

°	NULL
M	NULL
concen-trations	NULL
:	NULL
BMLFI	NULL
279-288	NULL
(	NULL
@	NULL
)	NULL
,	NULL
280-288	NULL
(	NULL
W	NULL
)	NULL
,	NULL
and	NULL
280-289	NULL
(	NULL
@	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
all	NULL
assays	NULL
were	NULL
conducted	NULL
at	NULL
an	NULL
E/T	NULL
ratio	NULL
of	NULL
5:1.	NULL
population	NULL
ex	NULL
vivo	NULL
and	NULL
,	NULL
in	NULL
fact	NULL
,	NULL
appeared	NULL
to	NULL
be	NULL
as	NULL
strong	NULL
as	NULL
the	NULL
immunodominant	NULL
latent	NULL
antigen-specific	NULL
response	NULL
recognizing	NULL
the	NULL
B7-restricted	NULL
EBN	NULL
A3A	NULL
379-387	NULL
epitope	NULL
.	NULL

Multiple	NULL
Lytic	NULL
Antigen-spedfic	NULL
Readivities	NULL
in	NULL
an	NULL
Individual	NULL
IM	NULL
Patient	NULL
.	NULL

Such	NULL
findings	NULL
suggested	NULL
that	NULL
one	NULL
might	NULL
be	NULL
able	NULL
to	NULL
identify	NULL
strong	NULL
lytic	NULL
antigen-specific	NULL
components	NULL
of	NULL
the	NULL
primary	NULL
EBV-induced	NULL
response	NULL
by	NULL
screening	NULL
the	NULL
primary	NULL
ex	NULL
vivo	NULL
effectors	NULL
on	NULL
autologous	NULL
LCL	NULL
targets	NULL
express	NULL
ing	NULL
individual	NULL
lytic	NULL
antigens	NULL
from	NULL
recombinant	NULL
vaccinia	NULL
vec-tors	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
latent	NULL
antigen	NULL
reactivities	NULL
in	NULL
IM	NULL
T	NULL
cell	NULL
populations	NULL
is	NULL
a	NULL
complicating	NULL
factor	NULL
since	NULL
these	NULL
will	NULL
produce	NULL
significant	NULL
baseline	NULL
levels	NULL
of	NULL
autologous	NULL
LCL	NULL
killing	NULL
;	NULL
in	NULL
practice	NULL
,	NULL
however	NULL
,	NULL
the	NULL
levels	NULL
are	NULL
often	NULL
sufficiently	NULL
low	NULL
to	NULL
allow	NULL
incremental	NULL
lytic	NULL
antigen-specific	NULL
lysis	NULL
to	NULL
be	NULL
detected	NULL
in	NULL
recombinant	NULL
vaccinia	NULL
assays	NULL
.	NULL

The	NULL
point	NULL
is	NULL
illustrated	NULL
with	NULL
reference	NULL
to	NULL
another	NULL
IM	NULL
patient	NULL
,	NULL
IM55	NULL
(	NULL
HLA	NULL
A24	NULL
,	NULL
A32	NULL
,	NULL
CTL	NULL
Responses	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Lytic	NULL
Cycle	NULL
Antigens	NULL
A	NULL
IM69	NULL
ex	NULL
vivo	NULL
effectors	NULL
|__A2.01	NULL
epitopes	NULL
_|	NULL
,	NULL
B7	NULL
epitopes	NULL
___	NULL
;	NULL
30	NULL
-I	NULL
s	NULL
I	NULL
a	NULL
w	NULL
al	NULL
2	NULL
8	NULL
ok.	NULL
3	NULL
15	NULL
t	NULL
#	NULL
#	NULL
O	NULL
T-BMLFI	NULL
--	NULL
LMP2	NULL
_	NULL
EBNA	NULL
3A	NULL
'	NULL
EBNA	NULL
3C	NULL
_-_	NULL
no	NULL
\	NULL
280-288	NULL
329-337	NULL
379-387	NULL
_	NULL
881-891	NULL
A2.01	NULL
,	NULL
B7-matched	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
peptide	NULL
B	NULL
IM61	NULL
ex	NULL
vivo	NULL
effectors	NULL
|__	NULL
A2.01	NULL
epitopes	NULL
_	NULL
,	NULL
B7	NULL
epitopes	NULL
___	NULL
,	NULL
304	NULL
!	NULL

II	NULL
1	NULL
4	NULL
i	NULL
>	NULL
2	NULL
F=	NULL
)	NULL
g	NULL
15	NULL
©	NULL
a	NULL
s	NULL
BMLFI	NULL
--	NULL
LMP2	NULL
-	NULL
3A	NULL
EBNA	NULL
3C	NULL
-	NULL
no	NULL
\	NULL
280-288	NULL
329-337	NULL
379-387	NULL
_	NULL
881-891	NULL
peptide	NULL
|	NULL
'	NULL
Autologous	NULL
PHA	NULL
blasts	NULL
+	NULL
peptide	NULL
'	NULL
Figure	NULL
5	NULL
.	NULL

Screening	NULL
of	NULL
(	NULL
A	NULL
)	NULL
IM69	NULL
and	NULL
(	NULL
B	NULL
)	NULL
IM61	NULL
primary	NULL
effectors	NULL
im	NULL
mediately	NULL
ex	NULL
vivo	NULL
for	NULL
evidence	NULL
of	NULL
cytotoxicity	NULL
against	NULL
the	NULL
HLA-A2.01-restricted	NULL
epitope	NULL
BMLF1	NULL
280-288	NULL
.	NULL

Assays	NULL
were	NULL
conducted	NULL
on	NULL
autologous	NULL
or	NULL
on	NULL
HLA-A2.01	NULL
,	NULL
B7-matched	NULL
PHA	NULL
blast	NULL
targets	NULL
pretreated	NULL
with	NULL
the	NULL
BMLF1	NULL
280-288	NULL
peptide	NULL
,	NULL
with	NULL
another	NULL
A2.01-restricted	NULL
epitope	NULL
peptide	NULL
LMP2	NULL
329-337	NULL
,	NULL
with	NULL
the	NULL
B7-restricted	NULL
epitope	NULL
peptides	NULL
EBNA3A	NULL
379-387	NULL
and	NULL
EBNA3C	NULL
881-891	NULL
,	NULL
or	NULL
with	NULL
DMSO	NULL
alone	NULL
as	NULL
a	NULL
``	NULL
no	NULL
peptide	NULL
``	NULL
control	NULL
.	NULL

R	NULL
esults	NULL
are	NULL
expressed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
both	NULL
assays	NULL
were	NULL
conducted	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
100:1	NULL
(	NULL
EW	NULL
)	NULL
and	NULL
50:1	NULL
(	NULL
2	NULL
)	NULL
.	NULL

B13	NULL
,	NULL
B60	NULL
,	NULL
C3	NULL
,	NULL
C6	NULL
)	NULL
,	NULL
where	NULL
ex	NULL
vivo	NULL
assays	NULL
on	NULL
vaccinia-infected	NULL
LCL	NULL
targets	NULL
clearly	NULL
indicated	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
immunodominant	NULL
response	NULL
to	NULL
the	NULL
BMRFI1	NULL
protein	NULL
and	NULL
suggested	NULL
that	NULL
there	NULL
may	NULL
also	NULL
be	NULL
weaker	NULL
reactivities	NULL
against	NULL
BRLF1	NULL
,	NULL
BMLF1	NULL
,	NULL
and	NULL
BALF2	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
A	NULL
)	NULL
.	NULL

Subsequent	NULL
limiting	NULL
dilution	NULL
cloning	NULL
confirmed	NULL
that	NULL
these	NULL
individual	NULL
reactivities	NULL
were	NULL
indeed	NULL
present	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
most	NULL
frequently	NULL
detectable	NULL
lytic	NULL
reactivity	NULL
seen	NULL
in	NULL
the	NULL
clonal	NULL
analysis	NULL
was	NULL
against	NULL
the	NULL
BMRFI	NULL
protein	NULL
,	NULL
as	NULL
represented	NULL
by	NULL
IM55	NULL
clone	NULL
112	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
.	NULL

These	NULL
clones	NULL
proved	NULL
to	NULL
be	NULL
restricted	NULL
through	NULL
HLA-C3	NULL
and	NULL
cytotoxicity	NULL
assays	NULL
against	NULL
overlapping	NULL
15-mer	NULL
peptides	NULL
from	NULL
BMRFI1	NULL
identified	NULL
the	NULL
epitope	NULL
as	NULL
lying	NULL
within	NULL
the	NULL
region	NULL
BMRFI1	NULL
86-100	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
other	NULL
CD8+	NULL
CTL	NULL
clones	NULL
obtained	NULL
in	NULL
the	NULL
same	NULL
experiment	NULL
mapped	NULL
to	NULL
different	NULL
individual	NULL
target	NULL
antigens	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
B	NULL
)	NULL
and	NULL
showed	NULL
unique	NULL
patterns	NULL
of	NULL
1611	NULL
Steven	NULL
et	NULL
al	NULL
.	NULL

A	NULL
-	NULL
IM55	NULL
ex	NULL
vivo	NULL
effectors	NULL
40	NULL
2	NULL
2	NULL
3	NULL
20	NULL
5	NULL
&	NULL
a	NULL
5	NULL
t	NULL
,	NULL
\	NULL
H	NULL
BE	NULL
]	NULL
|	NULL
12	NULL
!	NULL

-	NULL
=-	NULL
=-	NULL
=-	NULL
'	NULL
a	NULL
Cl	NULL
u	NULL
``	NULL
-	NULL
-	NULL
xo	NULL
&	NULL
&	NULL
&	NULL
Bo	NULL
40	NULL
ko	NULL
Rk	NULL
&	NULL
&	NULL
&	NULL
Ro	NULL
J	NULL
4	NULL
ad	NULL
&	NULL
4	NULL
4	NULL
4	NULL
dQ	NULL
&	NULL
4	NULL
Ao	NULL
2	NULL
&	NULL
§	NULL
<	NULL
<	NULL
<	NULL
R	NULL
UY	NULL
2	NULL
mo	NULL
A	NULL
M0	NULL
fo	NULL
a	NULL
m	NULL
_	NULL
ma	NULL
m	NULL
ma	NULL
a	NULL
autologous	NULL
LCL	NULL
+	NULL
vace-B	NULL
-	NULL
IM55	NULL
clonal	NULL
effectors	NULL
-	NULL
c167	NULL
Lao	NULL
,	NULL
,	NULL
,	NULL
so	NULL
E	NULL
2	NULL
9	NULL
9	NULL
'S	NULL
20	NULL
'S	NULL
30	NULL
&	NULL
&	NULL
0	NULL
0	NULL
~~~~~	NULL
elin	NULL
'=	NULL
=	NULL
-=	NULL
mom	NULL
o-	NULL
zoo	NULL
ins	NULL
-o-mo	NULL
R	NULL
&	NULL
om	NULL
B	NULL
R	NULL
&	NULL
R	NULL
B	NULL
C	NULL
mo	NULL
L	NULL
&	NULL
i.	NULL
i	NULL
,	NULL
I	NULL
Ro	NULL
&	NULL
H	NULL
i	NULL
3	NULL
J	NULL
g	NULL
&	NULL
&	NULL
4	NULL
4	NULL
do	NULL
&	NULL
4	NULL
g	NULL
J	NULL
dws	NULL
&	NULL
4	NULL
4	NULL
]	NULL
~	NULL
J	NULL
N5	NULL
3	NULL
s	NULL
T	NULL
<	NULL
<	NULL
f	NULL
0	NULL
3	NULL
§	NULL
x	NULL
3	NULL
s	NULL
f	NULL
<	NULL
<	NULL
I	NULL
0	NULL
2	NULL
Immmmmmmmmml	NULL
m	NULL
a	NULL
a	NULL
&	NULL
m	NULL
a	NULL
a	NULL
m	NULL
a	NULL
t.	NULL
autologous	NULL
LCL	NULL
+	NULL
vace-	NULL
autologous	NULL
LCL	NULL
+	NULL
vace-c206	NULL
c145	NULL
4	NULL
9°	NULL
&	NULL
30	NULL
3	NULL
2	NULL
3	NULL
8	NULL
G	NULL
45s	NULL
3s	NULL
&	NULL
#	NULL
*T	NULL
ET	NULL
EB	NULL
Er	NULL
|e	NULL
0	NULL
T	NULL
s	NULL
o	NULL
s	NULL
ow	NULL
b	NULL
c	NULL
tr	NULL
digiffiidil	NULL
:	NULL
&	NULL
3	NULL
9	NULL
2	NULL
mmmgmmmmfém	NULL
mmmmgmmﬁmm	NULL
|	NULL
;	NULL
|	NULL
autologous	NULL
LCL	NULL
+	NULL
vace-	NULL
autologous	NULL
LCL	NULL
+	NULL
vace-Figure	NULL
6	NULL
.	NULL

-	NULL
Analysis	NULL
of	NULL
the	NULL
lytic	NULL
antigen-specific	NULL
primary	NULL
CTL	NULL
response	NULL
in	NULL
IM55	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Primary	NULL
effectors	NULL
,	NULL
depleted	NULL
of	NULL
CD16+*	NULL
NK	NULL
cells	NULL
were	NULL
assayed	NULL
immediately	NULL
ex	NULL
vivo	NULL
at	NULL
E/T	NULL
ratios	NULL
of	NULL
80:1	NULL
(	NULL
BI	NULL
)	NULL
and	NULL
40:1	NULL
(	NULL
2	NULL
)	NULL
against	NULL
autologous	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
vaccinia	NULL
recombinants	NULL
expressing	NULL
individual	NULL
lytic	NULL
cycle	NULL
genes	NULL
as	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CTL	NULL
clones	NULL
established	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
of	NULL
IM55	NULL
effectors	NULL
immediately	NULL
ex	NULL
vivo	NULL
were	NULL
likewise	NULL
tested	NULL
for	NULL
lytic	NULL
antigen	NULL
specificity	NULL
at	NULL
an	NULL
E/T	NULL
ratio	NULL
of	NULL
5:1	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
in	NULL
Fig	NULL
.	NULL

1.	NULL
restriction	NULL
when	NULL
tested	NULL
on	NULL
allogeneic	NULL
LCL	NULL
targets	NULL
infected	NULL
with	NULL
the	NULL
relevant	NULL
vaccinia	NULL
recombinant	NULL
.	NULL

Thus	NULL
,	NULL
IM55	NULL
c167	NULL
recognized	NULL
the	NULL
early	NULL
protein	NULL
BMLFI	NULL
in	NULL
the	NULL
context	NULL
of	NULL
HLA-A24	NULL
,	NULL
IM55	NULL
c206	NULL
recognized	NULL
the	NULL
early	NULL
protein	NULL
BALF2	NULL
in	NULL
the	NULL
context	NULL
of	NULL
HLA-C6	NULL
,	NULL
and	NULL
IM55	NULL
c145	NULL
recognized	NULL
the	NULL
immediate	NULL
early	NULL
protein	NULL
BRLF1	NULL
,	NULL
but	NULL
in	NULL
this	NULL
case	NULL
limited	NULL
cell	NULL
numbers	NULL
precluded	NULL
identification	NULL
of	NULL
the	NULL
restriction	NULL
element	NULL
.	NULL

Lytic	NULL
Antigen-spedfic	NULL
Responses	NULL
Detectable	NULL
in	NULL
CTL	NULL
Memory	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
lytic	NULL
antigen-specific	NULL
reactivities	NULL
within	NULL
the	NULL
primary	NULL
response	NULL
to	NULL
EBV	NULL
infection	NULL
led	NULL
us	NULL
to	NULL
ask	NULL
whether	NULL
similar	NULL
reactivities	NULL
were	NULL
ever	NULL
detectable	NULL
in	NULL
CTL	NULL
memory	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
from	NULL
the	NULL
data	NULL
on	NULL
IM	NULL
donors	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
that	NULL
autologous	NULL
LCL	NULL
stimulation	NULL
favors	NULL
the	NULL
in	NULL
vitro	NULL
expansion	NULL
of	NULL
latent	NULL
,	NULL
as	NULL
opposed	NULL
to	NULL
lytic	NULL
,	NULL
antigen	NULL
reactivities	NULL
We	NULL
nevertheless	NULL
examined	NULL
LCL-stimulated	NULL
memory	NULL
CTL	NULL
preparations	NULL
that	NULL
had	NULL
IM63	NULL
memory	NULL
c20	NULL
ALI	NULL
%	NULL
specific	NULL
lysis	NULL
pSGS	NULL
-	NULL
pSGS-	NULL
pSGS-	NULL
BZLFI	NULL
'-	NULL
no	NULL
|	NULL
BZLFI	NULL
_	NULL
EBNAL1	NULL
,	NULL
190-197	NULL
peptide	NULL
I	NULL
II	NULL
I	NULL
B8-matched	NULL
autologous	NULL
PHA	NULL
keratinocytes	NULL
blasts	NULL
+	NULL
peptide	NULL
B	NULL
.	NULL

-	NULL
KG	NULL
memory	NULL
c19	NULL
Pu	NULL
O	NULL
DJ	NULL
Un	NULL
%	NULL
specific	NULL
lysis	NULL
uninfected	NULL
-	NULL
vace-	NULL
vace-	NULL
_	NULL
BMLFI	NULL
no	NULL
|	NULL
BMLF1	NULL
_	NULL
BMRF1	NULL
|	NULL
265-273	NULL
peptide	NULL
|	NULL
t	NULL
'	NULL
autologous	NULL
IIautologous	NULL
PHA	NULL
fibroblasts	NULL
blasts	NULL
+	NULL
peptide	NULL
C.	NULL
__CG	NULL
memory	NULL
c14.1	NULL
20	NULL
%	NULL
specific	NULL
lysis	NULL
o	NULL
B39	NULL
_	NULL
B62	NULL
match	NULL
match	NULL
0	NULL
Vautologoug	NULL
A250	NULL
000	NULL
A28	NULL
|	NULL
match	NULL
match	NULL
|	NULL
I	NULL
I	NULL
HLA	NULL
class	NULL
I-matched	NULL
LCL	NULL
+	NULL
vace-BALF2	NULL
Figure	NULL
7	NULL
.	NULL

-	NULL
Screening	NULL
of	NULL
memory	NULL
CTL	NULL
clones	NULL
for	NULL
lytic	NULL
antigen	NULL
specificity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
IM63	NULL
memory	NULL
clone	NULL
20	NULL
,	NULL
derived	NULL
from	NULL
donor	NULL
IM63	NULL
9	NULL
mo	NULL
after	NULL
recovery	NULL
from	NULL
the	NULL
primary	NULL
infection	NULL
,	NULL
was	NULL
tested	NULL
against	NULL
HLA-B8-matched	NULL
keratinocyte	NULL
targets	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
pSGS5-BZLF1	NULL
plasmid	NULL
or	NULL
with	NULL
pSG5	NULL
or	NULL
pSG5	NULL
EBNA1	NULL
as	NULL
controls	NULL
,	NULL
and	NULL
against	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
which	NULL
had	NULL
been	NULL
preexposed	NULL
to	NULL
the	NULL
BZLFI1	NULL
190-197	NULL
peptide	NULL
at	NULL
2	NULL
g/ml	NULL
or	NULL
to	NULL
DMSO	NULL
alone	NULL
as	NULL
a	NULL
no	NULL
peptide	NULL
control	NULL
.	NULL

(	NULL
B	NULL
)	NULL
KG	NULL
memory	NULL
clone	NULL
19	NULL
,	NULL
derived	NULL
from	NULL
long-term	NULL
virus	NULL
carrier	NULL
KG	NULL
,	NULL
was	NULL
tested	NULL
against	NULL
autologous	NULL
fibroblast	NULL
targets	NULL
,	NULL
either	NULL
uninfected	NULL
or	NULL
infected	NULL
with	NULL
the	NULL
vace-BMLF1	NULL
or	NULL
vacc-BMRFI1	NULL
recombinants	NULL
,	NULL
and	NULL
against	NULL
autologous	NULL
PHA	NULL
blast	NULL
targets	NULL
preexposed	NULL
to	NULL
the	NULL
BMLFI	NULL
265-273	NULL
peptide	NULL
at	NULL
2	NULL
g/ml	NULL
or	NULL
to	NULL
DMSO	NULL
alone	NULL
as	NULL
a	NULL
no	NULL
peptide	NULL
control	NULL
.	NULL

(	NULL
C	NULL
)	NULL
CG	NULL
memory	NULL
clone	NULL
14.1	NULL
,	NULL
derived	NULL
from	NULL
long-term	NULL
virus	NULL
carrier	NULL
CG	NULL
,	NULL
was	NULL
tested	NULL
against	NULL
the	NULL
vace-BALF2-infected	NULL
autologous	NULL
LCLs	NULL
and	NULL
against	NULL
a	NULL
range	NULL
of	NULL
vace-BALF2-infected	NULL
allogeneic	NULL
LCL	NULL
s	NULL
sharing	NULL
individual	NULL
HLA	NULL
class	NULL
I	NULL
alleles	NULL
with	NULL
donor	NULL
CG	NULL
as	NULL
indicated	NULL
.	NULL

1612	NULL
been	NULL
reactivated	NULL
in	NULL
vitro	NULL
from	NULL
blood	NULL
samples	NULL
of	NULL
IM	NULL
patients	NULL
53	NULL
,	NULL
59	NULL
,	NULL
and	NULL
63	NULL
taken	NULL
9-21	NULL
mo	NULL
after	NULL
the	NULL
resolution	NULL
of	NULL
their	NULL
symptoms	NULL
.	NULL

These	NULL
preparations	NULL
were	NULL
dominated	NULL
by	NULL
latent	NULL
antigen-specific	NULL
reactivities	NULL
(	NULL
in	NULL
particular	NULL
the	NULL
B	NULL
&	NULL
8-restricted	NULL
responses	NULL
to	NULL
EBN	NULL
A3A	NULL
epitopes	NULL
)	NULL
;	NULL
however	NULL
,	NULL
significant	NULL
recognition	NULL
of	NULL
the	NULL
BZLFI1	NULL
190-197	NULL
epitope	NULL
was	NULL
clearly	NULL
observed	NULL
using	NULL
the	NULL
IM59	NULL
memory	NULL
line	NULL
while	NULL
the	NULL
borderline	NULL
levels	NULL
of	NULL
lysis	NULL
seen	NULL
in	NULL
assays	NULL
with	NULL
the	NULL
IM63	NULL
memory	NULL
line	NULL
led	NULL
us	NULL
to	NULL
examine	NULL
this	NULL
population	NULL
further	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
.	NULL

Of	NULL
86	NULL
clones	NULL
generated	NULL
,	NULL
42	NULL
were	NULL
specific	NULL
for	NULL
one	NULL
or	NULL
other	NULL
of	NULL
the	NULL
B8-restricted	NULL
epitopes	NULL
in	NULL
EBN	NULL
A3A	NULL
but	NULL
7	NULL
clearly	NULL
recognized	NULL
the	NULL
B8-restricted	NULL
BZLF1	NULL
epitope	NULL
.	NULL

These	NULL
are	NULL
represented	NULL
by	NULL
IM63	NULL
memory	NULL
c20	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
A	NULL
)	NULL
which	NULL
showed	NULL
strong	NULL
lysis	NULL
of	NULL
BZLFI1	NULL
190-197	NULL
peptide-loaded	NULL
target	NULL
cells	NULL
and	NULL
also	NULL
of	NULL
B8-positive	NULL
keratinocytes	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
BZLF1	NULL
plasmid	NULL
expression	NULL
vector	NULL
.	NULL

Finally	NULL
we	NULL
went	NULL
on	NULL
to	NULL
screen	NULL
panels	NULL
of	NULL
limiting	NULL
dilution	NULL
clones	NULL
established	NULL
from	NULL
early	NULL
passage	NULL
memory	NULL
CTL	NULL
lines	NULL
of	NULL
two	NULL
long-term	NULL
virus	NULL
carriers	NULL
.	NULL

In	NULL
donor	NULL
KG	NULL
(	NULL
HLA-A30	NULL
,	NULL
A32	NULL
,	NULL
B44	NULL
,	NULL
B47	NULL
,	NULL
C5	NULL
,	NULL
C6	NULL
)	NULL
,	NULL
the	NULL
bulk	NULL
of	NULL
the	NULL
LCL-reactivated	NULL
clonal	NULL
response	NULL
mapped	NULL
to	NULL
a	NULL
latent	NULL
cycle	NULL
antigen	NULL
EBN	NULL
ABC	NULL
.	NULL

However	NULL
,	NULL
1	NULL
of	NULL
the	NULL
19	NULL
clones	NULL
analyzed	NULL
clearly	NULL
recognized	NULL
autologous	NULL
targets	NULL
infected	NULL
with	NULL
the	NULL
vacc-BMLF1	NULL
recombinant	NULL
.	NULL

This	NULL
CD8+*	NULL
clone	NULL
,	NULL
KG	NULL
memory	NULL
c19	NULL
,	NULL
was	NULL
subsequently	NULL
found	NULL
to	NULL
be	NULL
specific	NULL
for	NULL
the	NULL
9-mer	NULL
peptide	NULL
epitope	NULL
BMLFI	NULL
265-273	NULL
,	NULL
KDTWLDAR	NULL
M	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
B	NULL
)	NULL
;	NULL
the	NULL
inability	NULL
to	NULL
identify	NULL
a	NULL
restriction	NULL
element	NULL
for	NULL
this	NULL
clone	NULL
(	NULL
despite	NULL
assays	NULL
on	NULL
a	NULL
range	NULL
of	NULL
allogeneic	NULL
backgrounds	NULL
)	NULL
probably	NULL
reflects	NULL
the	NULL
fact	NULL
that	NULL
donor	NULL
KG	NULL
possesses	NULL
a	NULL
number	NULL
of	NULL
HLA	NULL
alleles	NULL
,	NULL
in	NULL
particular	NULL
A30	NULL
,	NULL
for	NULL
which	NULL
the	NULL
subtypes	NULL
are	NULL
not	NULL
yet	NULL
completely	NULL
defined	NULL
.	NULL

In	NULL
a	NULL
second	NULL
individual	NULL
,	NULL
CG	NULL
,	NULL
the	NULL
LCL-reactivated	NULL
CTL	NULL
response	NULL
was	NULL
again	NULL
dominated	NULL
by	NULL
clones	NULL
reactive	NULL
to	NULL
the	NULL
latent	NULL
cycle	NULL
antigen	NULL
EBN	NULL
A3C	NULL
;	NULL
however	NULL
,	NULL
one	NULL
of	NULL
the	NULL
56	NULL
EBV-specific	NULL
clones	NULL
established	NULL
from	NULL
this	NULL
donor	NULL
,	NULL
CG	NULL
memory	NULL
c14.1	NULL
,	NULL
consistently	NULL
recognized	NULL
the	NULL
early	NULL
lytic	NULL
antigen	NULL
BALF2	NULL
and	NULL
was	NULL
restricted	NULL
through	NULL
HLA-B39	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
C	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
even	NULL
using	NULL
this	NULL
relatively	NULL
inefficient	NULL
means	NULL
of	NULL
CTL	NULL
reactivation	NULL
,	NULL
lytic	NULL
antigen-specific	NULL
responses	NULL
were	NULL
detectable	NULL
in	NULL
the	NULL
CTL	NULL
memory	NULL
of	NULL
both	NULL
long-term	NULL
virus	NULL
carriers	NULL
analyzed	NULL
.	NULL

Discussion	NULL
Attempts	NULL
to	NULL
probe	NULL
the	NULL
memory	NULL
CTL	NULL
pool	NULL
of	NULL
EBV	NULL
carriers	NULL
for	NULL
evidence	NULL
of	NULL
lytic	NULL
antigen-specific	NULL
responses	NULL
have	NULL
for	NULL
many	NULL
years	NULL
been	NULL
frustrated	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
ready	NULL
source	NULL
of	NULL
infected	NULL
cells	NULL
for	NULL
use	NULL
as	NULL
in	NULL
vitro	NULL
stimulators	NULL
.	NULL

Bypassing	NULL
the	NULL
problem	NULL
by	NULL
stimulating	NULL
with	NULL
pooled	NULL
peptides	NULL
(	NULL
30	NULL
)	NULL
may	NULL
well	NULL
uncover	NULL
isolated	NULL
peptide-specific	NULL
reactivities	NULL
,	NULL
but	NULL
can	NULL
not	NULL
provide	NULL
an	NULL
overall	NULL
picture	NULL
either	NULL
of	NULL
the	NULL
relative	NULL
frequency	NULL
or	NULL
of	NULL
the	NULL
diversity	NULL
of	NULL
lytic	NULL
cycle	NULL
responses	NULL
which	NULL
an	NULL
antigenically	NULL
rich	NULL
herpesvirus	NULL
such	NULL
as	NULL
EBV	NULL
might	NULL
in-duce	NULL
.	NULL

Here	NULL
we	NULL
describe	NULL
a	NULL
different	NULL
experimental	NULL
strategy	NULL
which	NULL
has	NULL
wider	NULL
applicability	NULL
and	NULL
which	NULL
exploits	NULL
methods	NULL
first	NULL
developed	NULL
to	NULL
analyze	NULL
the	NULL
primary	NULL
CTL	NULL
response	NULL
to	NULL
EBV	NULL
latently	NULL
infected	NULL
cells	NULL
as	NULL
seen	NULL
in	NULL
IM	NULL
patients	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
initial	NULL
CTL	NULL
Responses	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Lytic	NULL
Cycle	NULL
Antigens	NULL
experiments	NULL
deliberately	NULL
focused	NULL
on	NULL
patients	NULL
with	NULL
the	NULL
HLA-B8	NULL
allele	NULL
since	NULL
this	NULL
was	NULL
the	NULL
restriction	NULL
element	NULL
for	NULL
the	NULL
putative	NULL
BZLFI	NULL
190-197	NULL
epitope	NULL
identified	NULL
by	NULL
peptide	NULL
stimulation	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Using	NULL
ex	NULL
vivo	NULL
primary	NULL
effectors	NULL
,	NULL
we	NULL
observed	NULL
strong	NULL
reactivity	NULL
to	NULL
BZLFI	NULL
190-197	NULL
in	NULL
all	NULL
three	NULL
patients	NULL
tested	NULL
,	NULL
with	NULL
levels	NULL
of	NULL
lysis	NULL
being	NULL
higher	NULL
than	NULL
those	NULL
seen	NULL
in	NULL
the	NULL
same	NULL
assays	NULL
against	NULL
two	NULL
immunodominant	NULL
latent	NULL
cycle	NULL
epitopes	NULL
,	NULL
EBN	NULL
A3A	NULL
325-333	NULL
and	NULL
158-166	NULL
,	NULL
again	NULL
restricted	NULL
through	NULL
HLA-B8	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A-C	NULL
)	NULL
.	NULL

We	NULL
have	NULL
already	NULL
shown	NULL
that	NULL
these	NULL
EBN	NULL
A3A	NULL
reactivities	NULL
constitute	NULL
>	NULL
1	NULL
%	NULL
of	NULL
the	NULL
circulating	NULL
CD8*	NULL
T	NULL
cell	NULL
pool	NULL
in	NULL
these	NULL
particular	NULL
patients	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
the	NULL
implication	NULL
is	NULL
that	NULL
the	NULL
BZLF1	NULL
epitope-specific	NULL
effectors	NULL
are	NULL
even	NULL
more	NULL
abundant	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
a	NULL
recent	NULL
report	NULL
has	NULL
raised	NULL
the	NULL
possibility	NULL
that	NULL
EBV	NULL
lytically	NULL
infected	NULL
cells	NULL
may	NULL
be	NULL
capable	NULL
of	NULL
inducing	NULL
a	NULL
superantigen-like	NULL
prolif-erative	NULL
T	NULL
cell	NULL
response	NULL
in	NULL
vitro	NULL
(	NULL
40	NULL
)	NULL
.	NULL

So	NULL
far	NULL
,	NULL
an	NULL
equivalent	NULL
effect	NULL
has	NULL
not	NULL
been	NULL
observed	NULL
in	NULL
vivo	NULL
,	NULL
and	NULL
indeed	NULL
,	NULL
the	NULL
analysis	NULL
of	NULL
VB	NULL
subset	NULL
distribution	NULL
and	NULL
T	NULL
cell	NULL
receptor	NULL
usage	NULL
among	NULL
IM	NULL
T	NULL
cells	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
CD8*	NULL
T	NULL
cell	NULL
expansions	NULL
seen	NULL
during	NULL
primary	NULL
EBV	NULL
infection	NULL
are	NULL
antigen	NULL
driven	NULL
,	NULL
rather	NULL
than	NULL
superantigen	NULL
driven	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
present	NULL
work	NULL
indicates	NULL
that	NULL
specific	NULL
responses	NULL
to	NULL
EBV	NULL
lytic	NULL
as	NULL
well	NULL
as	NULL
to	NULL
EBV	NULL
latent	NULL
antigens	NULL
may	NULL
contribute	NULL
to	NULL
these	NULL
T	NULL
cell	NULL
expan-sions	NULL
.	NULL

It	NULL
was	NULL
possible	NULL
to	NULL
grow	NULL
the	NULL
lytic	NULL
antigen-specific	NULL
effectors	NULL
from	NULL
IM	NULL
blood	NULL
in	NULL
vitro	NULL
by	NULL
stimulating	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
,	NULL
but	NULL
the	NULL
resultant	NULL
polyclonal	NULL
T	NULL
cell	NULL
line	NULL
gradually	NULL
became	NULL
dominated	NULL
by	NULL
CTLs	NULL
recognizing	NULL
the	NULL
latent	NULL
cycle	NULL
epitopes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
C-E	NULL
)	NULL
.	NULL

This	NULL
is	NULL
perhaps	NULL
not	NULL
surprising	NULL
since	NULL
the	NULL
stimulator	NULL
LCLs	NULL
are	NULL
latently	NULL
infected	NULL
lines	NULL
with	NULL
<	NULL
5	NULL
%	NULL
cells	NULL
in	NULL
lytic	NULL
cycle	NULL
and	NULL
express	NULL
the	NULL
relevant	NULL
BZLF1	NULL
antigen	NULL
.	NULL

However	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
BZLF1-specific	NULL
(	NULL
and	NULL
other	NULL
lytic	NULL
antigen-specific	NULL
)	NULL
CTLs	NULL
could	NULL
be	NULL
isolated	NULL
away	NULL
from	NULL
the	NULL
latent	NULL
cycle	NULL
response	NULL
by	NULL
limiting	NULL
dilution	NULL
cloning	NULL
of	NULL
IM	NULL
T	NULL
cells	NULL
immediately	NULL
ex	NULL
vivo	NULL
.	NULL

This	NULL
produced	NULL
numerous	NULL
CTL	NULL
clones	NULL
from	NULL
IM53	NULL
,	NULL
IM59	NULL
,	NULL
and	NULL
IM63	NULL
which	NULL
clearly	NULL
recognized	NULL
the	NULL
BZLFI1	NULL
190-197	NULL
epitope	NULL
peptide	NULL
but	NULL
,	NULL
interestingly	NULL
,	NULL
not	NULL
target	NULL
cells	NULL
expressing	NULL
BZLFI	NULL
from	NULL
recombinant	NULL
vaccinia	NULL
vectors	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
observed	NULL
using	NULL
LCL-stimulated	NULL
memory	NULL
CTL	NULL
clones	NULL
reactive	NULL
to	NULL
the	NULL
same	NULL
BZLF1	NULL
epitope	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Such	NULL
findings	NULL
were	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
observations	NULL
of	NULL
Bogedain	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
)	NULL
who	NULL
reported	NULL
significant	NULL
lysis	NULL
of	NULL
vace-	NULL
BZLF1-infected	NULL
targets	NULL
by	NULL
peptide-stimulated	NULL
CTLs	NULL
.	NULL

Concerned	NULL
by	NULL
this	NULL
dis	NULL
crepancy	NULL
,	NULL
we	NULL
went	NULL
on	NULL
to	NULL
show	NULL
that	NULL
BZLFI	NULL
epitope-specific	NULL
clones	NULL
both	NULL
from	NULL
the	NULL
primary	NULL
and	NULL
from	NULL
the	NULL
memory	NULL
response	NULL
did	NULL
recognize	NULL
target	NULL
cells	NULL
expressing	NULL
BZLF1	NULL
from	NULL
a	NULL
transiently	NULL
transfected	NULL
plasmid	NULL
vector	NULL
(	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
7	NULL
A	NULL
)	NULL
.	NULL

This	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
CTL	NULL
response	NULL
seen	NULL
in	NULL
HLA-B8-positive	NULL
IM	NULL
patients	NULL
is	NULL
indeed	NULL
BZLF1-specific	NULL
and	NULL
that	NULL
processing	NULL
of	NULL
the	NULL
BZLF1	NULL
190-197	NULL
epitope	NULL
is	NULL
somehow	NULL
impaired	NULL
in	NULL
vaccinia-infected	NULL
cells	NULL
There	NULL
are	NULL
other	NULL
,	NULL
albeit	NULL
rare	NULL
,	NULL
examples	NULL
of	NULL
inappropriate	NULL
processing	NULL
of	NULL
vaccinia-expressed	NULL
antigens	NULL
in	NULL
the	NULL
literature	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
can	NULL
not	NULL
entirely	NULL
discount	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
lytic	NULL
cycle	NULL
epitopes	NULL
,	NULL
perhaps	NULL
other	NULL
BZLF1	NULL
epitopes	NULL
,	NULL
have	NULL
gone	NULL
undetected	NULL
in	NULL
our	NULL
assays	NULL
.	NULL

1613	NULL
Steven	NULL
et	NULL
al	NULL
.	NULL

It	NULL
is	NULL
nevertheless	NULL
clear	NULL
that	NULL
EBV	NULL
infection	NULL
induces	NULL
abundant	NULL
CD8+*	NULL
CTL	NULL
reactivities	NULL
to	NULL
a	NULL
range	NULL
of	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
lytic	NULL
cycle	NULL
proteins	NULL
.	NULL

Thus	NULL
,	NULL
even	NULL
within	NULL
the	NULL
original	NULL
panel	NULL
of	NULL
three	NULL
IM	NULL
donors	NULL
with	NULL
immunodominant	NULL
BZLF1-specific	NULL
responses	NULL
,	NULL
clonal	NULL
analysis	NULL
revealed	NULL
additional	NULL
subdominant	NULL
CTL	NULL
reactivities	NULL
against	NULL
an	NULL
HLA-A2.05-restricted	NULL
epitope	NULL
in	NULL
the	NULL
immediate	NULL
early	NULL
protein	NULL
BRLF1	NULL
,	NULL
against	NULL
an	NULL
HLA-C6-restricted	NULL
epitope	NULL
in	NULL
the	NULL
early	NULL
protein	NULL
BMRFI	NULL
,	NULL
and	NULL
against	NULL
an	NULL
HLA-Bl8-restricted	NULL
epitope	NULL
in	NULL
another	NULL
early	NULL
protein	NULL
,	NULL
BMLFI1	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Extending	NULL
the	NULL
work	NULL
to	NULL
other	NULL
IM	NULL
patients	NULL
with	NULL
different	NULL
HLA	NULL
types	NULL
,	NULL
we	NULL
quickly	NULL
identified	NULL
individuals	NULL
where	NULL
BMRFI	NULL
(	NULL
see	NULL
IM55	NULL
,	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
and	NULL
BMLF1	NULL
(	NULL
see	NULL
IM61	NULL
and	NULL
IM69	NULL
,	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
provided	NULL
immunodominant	NULL
epitopes	NULL
for	NULL
the	NULL
primary	NULL
virus-induced	NULL
CTL	NULL
response	NULL
;	NULL
in	NULL
these	NULL
cases	NULL
,	NULL
lysis	NULL
of	NULL
the	NULL
relevant	NULL
early	NULL
lytic	NULL
cycle	NULL
protein	NULL
was	NULL
easily	NULL
detectable	NULL
in	NULL
ex	NULL
vivo	NULL
assays	NULL
with	NULL
fresh	NULL
IM	NULL
effectors	NULL
and	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
subsequently	NULL
derived	NULL
CTL	NULL
clones	NULL
displayed	NULL
the	NULL
same	NULL
specificity	NULL
.	NULL

The	NULL
above	NULL
BMLFI	NULL
reactivity	NULL
was	NULL
particularly	NULL
interesting	NULL
since	NULL
it	NULL
was	NULL
restricted	NULL
through	NULL
the	NULL
allele	NULL
,	NULL
a	NULL
molecule	NULL
which	NULL
is	NULL
consistently	NULL
a	NULL
weak	NULL
restriction	NULL
element	NULL
for	NULL
latent	NULL
antigen-specific	NULL
responses	NULL
(	NULL
8	NULL
,	NULL
9	NULL
)	NULL
,	NULL
yet	NULL
which	NULL
clearly	NULL
can	NULL
mediate	NULL
a	NULL
strong	NULL
response	NULL
to	NULL
lytically	NULL
infected	NULL
cells	NULL
.	NULL

Table	NULL
1	NULL
presents	NULL
a	NULL
summary	NULL
of	NULL
the	NULL
CTL	NULL
reactivities	NULL
identified	NULL
in	NULL
the	NULL
course	NULL
of	NULL
this	NULL
work	NULL
.	NULL

It	NULL
should	NULL
be	NULL
stressed	NULL
that	NULL
our	NULL
study	NULL
has	NULL
concentrated	NULL
on	NULL
a	NULL
limited	NULL
number	NULL
of	NULL
viral	NULL
proteins	NULL
,	NULL
mainly	NULL
of	NULL
the	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
subsets	NULL
,	NULL
and	NULL
is	NULL
by	NULL
no	NULL
means	NULL
a	NULL
comprehensive	NULL
survey	NULL
of	NULL
the	NULL
full	NULL
range	NULL
of	NULL
potential	NULL
target	NULL
antigens	NULL
expressed	NULL
during	NULL
the	NULL
EBV	NULL
lytic	NULL
cycle	NULL
.	NULL

Of	NULL
the	NULL
antigens	NULL
tested	NULL
,	NULL
BZLF1	NULL
and	NULL
BRLFI	NULL
are	NULL
the	NULL
best	NULL
known	NULL
immediate	NULL
early	NULL
proteins	NULL
and	NULL
are	NULL
expressed	NULL
at	NULL
the	NULL
very	NULL
initiation	NULL
of	NULL
lytic	NULL
cycle	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Together	NULL
these	NULL
activate	NULL
the	NULL
expression	NULL
of	NULL
at	NULL
least	NULL
four	NULL
of	NULL
the	NULL
early	NULL
proteins	NULL
studied	NULL
here	NULL
,	NULL
namely	NULL
BMLF1	NULL
,	NULL
itself	NULL
a	NULL
transactivator	NULL
(	NULL
44	NULL
)	NULL
,	NULL
BMRFI1	NULL
,	NULL
a	NULL
processivity	NULL
factor	NULL
involved	NULL
in	NULL
viral	NULL
DN	NULL
A	NULL
replication	NULL
(	NULL
45	NULL
)	NULL
,	NULL
BHLF1	NULL
,	NULL
an	NULL
early	NULL
antigen	NULL
EA-D	NULL
component	NULL
of	NULL
unknown	NULL
function	NULL
(	NULL
46	NULL
)	NULL
,	NULL
and	NULL
BHRF1	NULL
,	NULL
the	NULL
viral	NULL
homologue	NULL
of	NULL
cellular	NULL
Bel-2	NULL
(	NULL
47	NULL
)	NULL
;	NULL
the	NULL
two	NULL
other	NULL
early	NULL
proteins	NULL
,	NULL
BALF2	NULL
and	NULL
BALF5	NULL
,	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
viral	NULL
DNA	NULL
replication	NULL
as	NULL
the	NULL
major	NULL
DNA	NULL
binding	NULL
protein	NULL
and	NULL
the	NULL
viral	NULL
DN	NULL
A	NULL
poly-merase	NULL
,	NULL
respectively	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
only	NULL
evidence	NULL
to	NULL
date	NULL
that	NULL
any	NULL
of	NULL
these	NULL
early	NULL
proteins	NULL
contain	NULL
T	NULL
cell	NULL
epitopes	NULL
is	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
HLA	NULL
class	NULL
II-restricted	NULL
response	NULL
to	NULL
BHRFI	NULL
in	NULL
an	NULL
IM	NULL
patient	NULL
(	NULL
48	NULL
)	NULL
.	NULL

It	NULL
therefore	NULL
seems	NULL
significant	NULL
that	NULL
the	NULL
present	NULL
analysis	NULL
,	NULL
though	NULL
limited	NULL
to	NULL
a	NULL
small	NULL
number	NULL
of	NULL
do-nors	NULL
,	NULL
nevertheless	NULL
revealed	NULL
responses	NULL
to	NULL
both	NULL
of	NULL
the	NULL
immediate	NULL
early	NULL
proteins	NULL
and	NULL
to	NULL
three	NULL
of	NULL
the	NULL
six	NULL
early	NULL
proteins	NULL
tested	NULL
;	NULL
these	NULL
responses	NULL
involved	NULL
a	NULL
minimum	NULL
of	NULL
eight	NULL
different	NULL
epitopes	NULL
and	NULL
a	NULL
minimum	NULL
of	NULL
nine	NULL
different	NULL
restriction	NULL
el-ements	NULL
.	NULL

Although	NULL
most	NULL
were	NULL
identified	NULL
through	NULL
the	NULL
analysis	NULL
of	NULL
primary	NULL
CTLs	NULL
from	NULL
IM	NULL
patients	NULL
,	NULL
it	NULL
is	NULL
noteworthy	NULL
that	NULL
lytic	NULL
antigen-specific	NULL
responses	NULL
are	NULL
also	NULL
detectable	NULL
in	NULL
CTL	NULL
memory	NULL
,	NULL
even	NULL
using	NULL
the	NULL
relatively	NULL
inefficient	NULL
strategy	NULL
of	NULL
in	NULL
vitro	NULL
reactivation	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
a	NULL
very	NULL
recent	NULL
paper	NULL
from	NULL
Scotet	NULL
et	NULL
al	NULL
.	NULL

(	NULL
49	NULL
)	NULL
described	NULL
the	NULL
isolation	NULL
of	NULL
BZLF1-	NULL
and	NULL
BMLF1-specific	NULL
CTL	NULL
clones	NULL
from	NULL
synovial	NULL
T	NULL
cells	NULL
infiltrating	NULL
the	NULL
affected	NULL
joints	NULL
Table	NULL
1	NULL
.	NULL

EBV	NULL
LyticAntigen-spedfic	NULL
CTL	NULL
Readivities	NULL
Epitope	NULL
EBV	NULL
antigen	NULL
location	NULL
,	NULL
sequence	NULL
HLA	NULL
restriction	NULL
CTL	NULL
donor*	NULL
BZLFI	NULL
190-197	NULL
,	NULL
RAKFKQLL	NULL
B8	NULL
IM53	NULL
,	NULL
IM	NULL
59	NULL
,	NULL
IM63	NULL
BRLFI	NULL
ND	NULL
A2.05	NULL
IM63	NULL
ND	NULL
ND	NULL
IM55	NULL
BMLFI	NULL
265-273	NULL
,	NULL
KDTWLDAR	NULL
M	NULL
ND	NULL
KG	NULL
280-288	NULL
,	NULL
GLCTLVAML	NULL
A2.01	NULL
IM61	NULL
,	NULL
IM69	NULL
397-405	NULL
,	NULL
DEVEFLGHY	NULL
B18	NULL
IM53	NULL
ND	NULL
A24	NULL
IM55	NULL
BMRFI	NULL
86-100	NULL
,	NULL
FRNLAYGRTCVLGKE	NULL
:	NULL
C3	NULL
IM55	NULL
268-276	NULL
,	NULL
YR	NULL
SGHAVV	NULL
C6	NULL
IM63	NULL
BALF2	NULL
ND	NULL
B39	NULL
CG	NULL
ND	NULL
C6	NULL
IM55	NULL
*	NULL
Assays	NULL
were	NULL
carried	NULL
out	NULL
on	NULL
ex	NULL
vivo	NULL
primary	NULL
effectors	NULL
from	NULL
IM53	NULL
,	NULL
IM55	NULL
,	NULL
IM59	NULL
,	NULL
IM61	NULL
,	NULL
IM63	NULL
,	NULL
and	NULL
IM69	NULL
,	NULL
on	NULL
in	NULL
vitro-expanded	NULL
polyclonal	NULL
primary	NULL
CTLs	NULL
from	NULL
IM53	NULL
,	NULL
IM59	NULL
,	NULL
and	NULL
IM63	NULL
,	NULL
on	NULL
in	NULL
vitro-expanded	NULL
primary	NULL
CTL	NULL
clones	NULL
from	NULL
IM53	NULL
,	NULL
IM55	NULL
,	NULL
IM59	NULL
,	NULL
IM63	NULL
,	NULL
and	NULL
IM69	NULL
,	NULL
on	NULL
in	NULL
vitro-expanded	NULL
polyclonal	NULL
memory	NULL
CTLs	NULL
from	NULL
post-IM53	NULL
,	NULL
post-IM59	NULL
,	NULL
and	NULL
post-IM63	NULL
,	NULL
and	NULL
on	NULL
in	NULL
vitro-expanded	NULL
memory	NULL
CTL	NULL
clones	NULL
from	NULL
post-IM63	NULL
,	NULL
KG	NULL
,	NULL
and	NULL
CG	NULL
.	NULL

*Miminal	NULL
epitope	NULL
not	NULL
yet	NULL
defined	NULL
.	NULL

of	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
patients	NULL
.	NULL

This	NULL
further	NULL
indicates	NULL
that	NULL
lytic	NULL
antigen-specific	NULL
T	NULL
cells	NULL
are	NULL
retained	NULL
in	NULL
long-term	NULL
virus	NULL
carriers	NULL
.	NULL

It	NULL
is	NULL
also	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
at	NULL
least	NULL
3	NULL
of	NULL
the	NULL
11	NULL
lytic	NULL
antigen-specific	NULL
responses	NULL
described	NULL
here	NULL
(	NULL
including	NULL
one	NULL
of	NULL
the	NULL
immunodominant	NULL
responses	NULL
)	NULL
were	NULL
restricted	NULL
through	NULL
HLA-C	NULL
rather	NULL
than	NULL
HLA-A	NULL
or	NULL
-B	NULL
alleles	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
peptide-stimulation	NULL
work	NULL
of	NULL
Bogedain	NULL
et	NULL
al	NULL
.	NULL

(	NULL
30	NULL
)	NULL
suggested	NULL
that	NULL
BZLF1	NULL
also	NULL
contained	NULL
a	NULL
C6-restricted	NULL
epitope	NULL
that	NULL
overlapped	NULL
the	NULL
B8	NULL
epitope	NULL
sequence	NULL
(	NULL
such	NULL
a	NULL
response	NULL
was	NULL
not	NULL
seen	NULL
in	NULL
the	NULL
present	NULL
study	NULL
)	NULL
,	NULL
whereas	NULL
an	NULL
earlier	NULL
paper	NULL
described	NULL
alloreactive	NULL
CTL	NULL
clones	NULL
which	NULL
showed	NULL
fortuitous	NULL
cross-recognition	NULL
of	NULL
EBV	NULL
lytic	NULL
antigen-positive	NULL
LCLs	NULL
only	NULL
if	NULL
they	NULL
expressed	NULL
the	NULL
HLA-C7	NULL
allele	NULL
(	NULL
50	NULL
)	NULL
.	NULL

The	NULL
use	NULL
of	NULL
HLA-C	NULL
as	NULL
a	NULL
restriction	NULL
element	NULL
appears	NULL
to	NULL
be	NULL
rare	NULL
amongst	NULL
CTLs	NULL
reactive	NULL
to	NULL
latent	NULL
cycle	NULL
antigens	NULL
(	NULL
24	NULL
)	NULL
,	NULL
possibly	NULL
reflecting	NULL
the	NULL
fact	NULL
that	NULL
HLA-C	NULL
antigens	NULL
are	NULL
expressed	NULL
at	NULL
only	NULL
5	NULL
%	NULL
of	NULL
the	NULL
level	NULL
of	NULL
HLA-A	NULL
or	NULL
-B	NULL
on	NULL
the	NULL
latently-	NULL
infected	NULL
LCL	NULL
surface	NULL
(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
present	NULL
findings	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
HLA-C	NULL
molecules	NULL
may	NULL
become	NULL
more	NULL
important	NULL
for	NULL
antigen	NULL
presentation	NULL
as	NULL
cells	NULL
switch	NULL
into	NULL
lytic	NULL
cycle	NULL
.	NULL

The	NULL
detection	NULL
of	NULL
such	NULL
potent	NULL
CTL	NULL
responses	NULL
to	NULL
lytic	NULL
cycle	NULL
antigens	NULL
is	NULL
an	NULL
important	NULL
step	NULL
forward	NULL
in	NULL
our	NULL
understanding	NULL
of	NULL
EBV	NULL
biology	NULL
since	NULL
it	NULL
strongly	NULL
suggests	NULL
that	NULL
foci	NULL
of	NULL
EBV	NULL
replication	NULL
are	NULL
subject	NULL
to	NULL
direct	NULL
CTL	NULL
control	NULL
in	NULL
vivo	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
fall	NULL
in	NULL
oropharyngeal	NULL
virus	NULL
shedding	NULL
that	NULL
occurs	NULL
with	NULL
recovery	NULL
from	NULL
acute	NULL
primary	NULL
infection	NULL
in	NULL
IM	NULL
(	NULL
2	NULL
)	NULL
is	NULL
very	NULL
probably	NULL
brought	NULL
about	NULL
by	NULL
the	NULL
emerging	NULL
lytic	NULL
antigen-specific	NULL
CTL	NULL
response	NULL
.	NULL

Likewise	NULL
,	NULL
the	NULL
recrudescence	NULL
of	NULL
virus	NULL
replication	NULL
seen	NULL
in	NULL
T	NULL
cell-immunocompromised	NULL
virus	NULL
carriers	NULL
(	NULL
10-12	NULL
,	NULL
52	NULL
)	NULL
is	NULL
probably	NULL
a	NULL
consequence	NULL
of	NULL
that	NULL
response	NULL
being	NULL
impaired	NULL
.	NULL

Although	NULL
the	NULL
present	NULL
work	NULL
does	NULL
not	NULL
allow	NULL
any	NULL
firm	NULL
conclusions	NULL
to	NULL
be	NULL
drawn	NULL
about	NULL
the	NULL
relative	NULL
immunogenicity	NULL
of	NULL
different	NULL
lytic	NULL
cycle	NULL
proteins	NULL
,	NULL
it	NULL
1614	NULL
does	NULL
clearly	NULL
show	NULL
that	NULL
EBV	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
proteins	NULL
are	NULL
frequent	NULL
targets	NULL
for	NULL
the	NULL
virus-induced	NULL
CTL	NULL
response	NULL
.	NULL

This	NULL
is	NULL
quite	NULL
different	NULL
from	NULL
the	NULL
situation	NULL
in	NULL
HSV	NULL
and	NULL
CMV	NULL
infection	NULL
where	NULL
particular	NULL
virus-coded	NULL
immediate	NULL
early	NULL
and/or	NULL
early	NULL
proteins	NULL
either	NULL
directly	NULL
inhibit	NULL
the	NULL
HLA	NULL
class	NULL
I	NULL
pathway	NULL
of	NULL
antigen	NULL
presentation	NULL
(	NULL
19	NULL
,	NULL
20	NULL
,	NULL
22	NULL
)	NULL
or	NULL
,	NULL
as	NULL
shown	NULL
recently	NULL
for	NULL
a	NULL
CMV	NULL
immediate	NULL
early	NULL
protein	NULL
,	NULL
are	NULL
selectively	NULL
protected	NULL
from	NULL
processing	NULL
(	NULL
53	NULL
)	NULL
.	NULL

As	NULL
a	NULL
conse-quence	NULL
,	NULL
human	NULL
CD8+*	NULL
CTL	NULL
responses	NULL
to	NULL
these	NULL
viruses	NULL
are	NULL
markedly	NULL
skewed	NULL
towards	NULL
structural	NULL
proteins	NULL
(	NULL
tegument	NULL
or	NULL
capsid	NULL
components	NULL
)	NULL
that	NULL
are	NULL
delivered	NULL
into	NULL
infected	NULL
cells	NULL
by	NULL
the	NULL
incoming	NULL
virus	NULL
particle	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

The	NULL
present	NULL
evidence	NULL
suggests	NULL
that	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
proteins	NULL
of	NULL
the	NULL
EBV	NULL
lytic	NULL
cycle	NULL
do	NULL
not	NULL
enjoy	NULL
such	NULL
immunological	NULL
protection	NULL
,	NULL
and	NULL
hence	NULL
,	NULL
that	NULL
EBV	NULL
may	NULL
not	NULL
have	NULL
evolved	NULL
such	NULL
effective	NULL
mechanisms	NULL
of	NULL
immune	NULL
interference	NULL
,	NULL
at	NULL
least	NULL
not	NULL
mechanisms	NULL
that	NULL
are	NULL
operative	NULL
right	NULL
from	NULL
the	NULL
initiation	NULL
of	NULL
lytic	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
context	NULL
,	NULL
it	NULL
is	NULL
worth	NULL
pointing	NULL
out	NULL
a	NULL
fundamental	NULL
difference	NULL
between	NULL
the	NULL
biology	NULL
of	NULL
y-herpesviruses	NULL
such	NULL
as	NULL
EBV	NULL
and	NULL
that	NULL
of	NULL
«	NULL
-	NULL
and	NULL
B-herpesviruses	NULL
such	NULL
as	NULL
HSV	NULL
and	NULL
CMV	NULL
.	NULL

For	NULL
any	NULL
herpesvirus	NULL
,	NULL
it	NULL
is	NULL
believed	NULL
that	NULL
establishing	NULL
a	NULL
large	NULL
pool	NULL
of	NULL
latently-	NULL
infected	NULL
cells	NULL
in	NULL
vivo	NULL
increases	NULL
the	NULL
subsequent	NULL
chances	NULL
of	NULL
successful	NULL
reactivation	NULL
and	NULL
transmission	NULL
to	NULL
a	NULL
new	NULL
host	NULL
(	NULL
54	NULL
,	NULL
55	NULL
)	NULL
.	NULL

y-herpesviruses	NULL
are	NULL
able	NULL
to	NULL
achieve	NULL
this	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
virus	NULL
replication	NULL
through	NULL
the	NULL
virus-driven	NULL
clonal	NULL
expansion	NULL
of	NULL
latently	NULL
infected	NULL
cells	NULL
;	NULL
«	NULL
-	NULL
and	NULL
B-herpesviruses	NULL
do	NULL
not	NULL
have	NULL
this	NULL
capac-ity	NULL
,	NULL
and	NULL
so	NULL
the	NULL
establishment	NULL
and	NULL
maintenance	NULL
of	NULL
their	NULL
latent	NULL
reservoir	NULL
is	NULL
much	NULL
more	NULL
dependent	NULL
upon	NULL
lytic	NULL
replication	NULL
of	NULL
the	NULL
virus	NULL
during	NULL
primary	NULL
infection	NULL
and/or	NULL
recrudescence	NULL
.	NULL

These	NULL
latter	NULL
agents	NULL
may	NULL
therefore	NULL
have	NULL
been	NULL
under	NULL
greater	NULL
evolutionary	NULL
pressure	NULL
to	NULL
reduce	NULL
their	NULL
susceptibility	NULL
to	NULL
immune	NULL
detection	NULL
during	NULL
lytic	NULL
cycle	NULL
.	NULL

CTL	NULL
Responses	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Lytic	NULL
Cycle	NULL
Antigens	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
(	NULL
MRC	NULL
)	NULL
and	NULL
the	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
,	NULL
U.K.	NULL
N.M.	NULL
Steven	NULL
is	NULL
a	NULL
MRC	NULL
Clinical	NULL
Research	NULL
Fellow	NULL
,	NULL
A.	NULL
Kumar	NULL
is	NULL
a	NULL
Lady	NULL
Tata	NULL
Memorial	NULL
Trust	NULL
Fellow	NULL
.	NULL

The	NULL
authors	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
M.	NULL
Mackett	NULL
for	NULL
providing	NULL
an	NULL
independently	NULL
constructed	NULL
vace-BZLF1	NULL
recom-binant	NULL
,	NULL
to	NULL
clinical	NULL
colleagues	NULL
in	NULL
the	NULL
Health	NULL
Centres	NULL
of	NULL
Birmingham	NULL
and	NULL
Aston	NULL
Universities	NULL
and	NULL
in	NULL
the	NULL
University	NULL
and	NULL
Heartlands	NULL
Hospitals	NULL
,	NULL
Birmingham	NULL
,	NULL
to	NULL
local	NULL
general	NULL
practitioners	NULL
for	NULL
access	NULL
to	NULL
patients	NULL
,	NULL
to	NULL
Sr.	NULL
P.	NULL
O	NULL
gan	NULL
for	NULL
blood	NULL
collection	NULL
,	NULL
and	NULL
to	NULL
Deborah	NULL
Williams	NULL
for	NULL
excellent	NULL
secretarial	NULL
help	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
A.B	NULL
.	NULL

Rickinson	NULL
,	NULL
CRC	NULL
Institute	NULL
for	NULL
Cancer	NULL
Studies	NULL
,	NULL
University	NULL
of	NULL
Birmingham	NULL
,	NULL
Birmingham	NULL
,	NULL
B15	NULL
2TT	NULL
,	NULL
U.K	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
7	NULL
November	NULL
1996	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
29	NULL
January	NULL
1997	NULL
.	NULL

References	NULL
1	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

Rickinson	NULL
,	NULL
A.B	NULL
.	NULL

,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
.	NULL

In	NULL
Fields	NULL
Virology	NULL
.	NULL

B.N	NULL
.	NULL

Fields	NULL
,	NULL
D.M	NULL
.	NULL

Knipe	NULL
,	NULL
and	NULL
P.M.	NULL
Howley	NULL
,	NULL
editors	NULL
.	NULL

Lippincott-Raven	NULL
Publishers	NULL
,	NULL
Philadelphia	NULL
2397-2446.	NULL
.	NULL

Sixbey	NULL
,	NULL
JW	NULL
.	NULL

,	NULL
J.G	NULL
.	NULL

Nedrud	NULL
,	NULL
N.	NULL
R	NULL
aab-Traub	NULL
,	NULL
R.A.	NULL
Hanes	NULL
,	NULL
and	NULL
J.S	NULL
.	NULL

Pagano	NULL
.	NULL

1984	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
replication	NULL
in	NULL
oropharyngeal	NULL
epithelial	NULL
cells	NULL
N.	NULL
Engl	NULL
J	NULL
Med	NULL
.	NULL

310:1225-1230.	NULL
.	NULL

Anagnostopoulos	NULL
,	NULL
I.	NULL
,	NULL
M.	NULL
Hummel	NULL
,	NULL
C.	NULL
Kreschel	NULL
,	NULL
and	NULL
H.	NULL
Stein	NULL
.	NULL

1995	NULL
.	NULL

Morphology	NULL
,	NULL
immunophenotype	NULL
and	NULL
distribution	NULL
of	NULL
latently	NULL
and/	NULL
or	NULL
productively	NULL
Epstein-Barr	NULL
virus-infected	NULL
cells	NULL
in	NULL
acute	NULL
infectious	NULL
mononucleosis	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
inter-individual	NULL
infection	NULL
route	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

Blood	NULL
85	NULL
:	NULL
744-750.	NULL
.	NULL

Tierney	NULL
,	NULL
R.J.	NULL
,	NULL
N.	NULL
Steven	NULL
,	NULL
LS	NULL
.	NULL

Young	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Rickinson	NULL
.	NULL

1994	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
latency	NULL
in	NULL
blood	NULL
mononuclear	NULL
cells	NULL
:	NULL
analysis	NULL
of	NULL
viral	NULL
gene	NULL
transcription	NULL
during	NULL
primary	NULL
infection	NULL
and	NULL
in	NULL
the	NULL
carrier	NULL
state	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

68:7374-7385.	NULL
.	NULL

Yao	NULL
,	NULL
Q.Y	NULL
.	NULL

,	NULL
P.	NULL
O	NULL
gan	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
M.	NULL
Wood	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

R	NULL
ickin-	NULL
son	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus-infected	NULL
B	NULL
cells	NULL
persist	NULL
in	NULL
the	NULL
circulation	NULL
of	NULL
acyclovir-treated	NULL
virus	NULL
carriers	NULL
.	NULL

Inf	NULL
.	NULL

J	NULL
Caner	NULL
.	NULL

43:67-71.	NULL
.	NULL

Miyashita	NULL
,	NULL
EM	NULL
.	NULL

,	NULL
B.	NULL
Yang	NULL
,	NULL
K.M.C	NULL
.	NULL

Lam	NULL
,	NULL
D.H.	NULL
Crawford	NULL
,	NULL
and	NULL
D.A	NULL
.	NULL

Thorley-Lawson	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
novel	NULL
form	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
latency	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Cell	NULL
.	NULL

80:593-601.	NULL
.	NULL

Steven	NULL
,	NULL
N.M.	NULL
,	NULL
A.M.	NULL
Leese	NULL
,	NULL
N.E	NULL
.	NULL

Annels	NULL
,	NULL
S.P	NULL
.	NULL

Lee	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Rickinson	NULL
.	NULL

1996	NULL
.	NULL

Epitope	NULL
focusing	NULL
in	NULL
the	NULL
primary	NULL
cytotoxic	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
relationship	NULL
to	NULL
T	NULL
cell	NULL
memory	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1801-1813.	NULL
.	NULL

Murray	NULL
,	NULL
R	NULL
.J	NULL
.	NULL

,	NULL
M.G	NULL
.	NULL

Kurilla	NULL
,	NULL
JM	NULL
.	NULL

Brooks	NULL
,	NULL
W.A	NULL
.	NULL

Thomas	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Rickinson	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
target	NULL
antigens	NULL
for	NULL
the	NULL
human	NULL
cytotoxic	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
immune	NULL
control	NULL
of	NULL
EBV-positive	NULL
malignancies	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
176:157-168.	NULL
.	NULL

Khanna	NULL
,	NULL
R.	NULL
,	NULL
SR.	NULL
Burrows	NULL
,	NULL
M.G	NULL
.	NULL

Kurilla	NULL
,	NULL
C.A	NULL
.	NULL

Jacob	NULL
,	NULL
LS	NULL
.	NULL

Misko	NULL
,	NULL
TB	NULL
.	NULL

Sculley	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
D.J	NULL
.	NULL

Moss	NULL
.	NULL

1992	NULL
.	NULL

Localization	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
cytotoxic	NULL
T	NULL
cell	NULL
epitopes	NULL
using	NULL
recombinant	NULL
vaccinia	NULL
:	NULL
implications	NULL
for	NULL
vaccine	NULL
development	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:169-178	NULL
.	NULL

Greenspan	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
D.	NULL
Greenspan	NULL
,	NULL
E.T	NULL
.	NULL

Lennette	NULL
,	NULL
D.I	NULL
.	NULL

Abrams	NULL
,	NULL
M.A	NULL
.	NULL

Conant	NULL
,	NULL
V.	NULL
Petersen	NULL
,	NULL
and	NULL
U.K.	NULL
Freese	NULL
.	NULL

1985	NULL
.	NULL

Replication	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
within	NULL
the	NULL
epithelial	NULL
cells	NULL
of	NULL
oral	NULL
``	NULL
hairy	NULL
``	NULL
leukoplakia	NULL
,	NULL
an	NULL
AIDS-associated	NULL
lesion	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J	NULL
Med	NULL
.	NULL

313:1564-1571	NULL
.	NULL

Andiman	NULL
,	NULL
W.A	NULL
.	NULL

,	NULL
R.	NULL
Eastman	NULL
,	NULL
K.	NULL
Martin	NULL
,	NULL
B.Z	NULL
.	NULL

Katz	NULL
,	NULL
A.	NULL
Ru	NULL
1615	NULL
Steven	NULL
et	NULL
al	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20.	NULL
binstein	NULL
,	NULL
J.	NULL
Pitt	NULL
,	NULL
S.	NULL
Pahura	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1985	NULL
.	NULL

Opportunistic	NULL
lymphoproliferations	NULL
associated	NULL
with	NULL
Epstein-Barr	NULL
viral	NULL
DNA	NULL
in	NULL
infants	NULL
and	NULL
children	NULL
with	NULL
AIDS	NULL
.	NULL

Lane	NULL
.	NULL

11:1390-1393	NULL
.	NULL

Thomas	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
F.	NULL
Cotter	NULL
,	NULL
A.M.	NULL
Hanby	NULL
,	NULL
LQ	NULL
.	NULL

Long	NULL
,	NULL
PR	NULL
.	NULL

Morgan	NULL
,	NULL
B.	NULL
Bramble	NULL
,	NULL
and	NULL
B.	NULL
Bailey	NULL
.	NULL

1993	NULL
.	NULL

Epstein-Barr	NULL
vi-rus-related	NULL
oral	NULL
T	NULL
cell	NULL
lymphoma	NULL
associated	NULL
with	NULL
human	NULL
im-munodeficiency	NULL
virus	NULL
immunosuppression	NULL
.	NULL

Blood	NULL
.	NULL

81:3350-3356	NULL
.	NULL

Egan	NULL
,	NULL
J.J.	NULL
,	NULL
J.P.	NULL
Stewart	NULL
,	NULL
P.S	NULL
.	NULL

Hasleton	NULL
,	NULL
J.R	NULL
.	NULL

Arrand	NULL
,	NULL
K.B	NULL
.	NULL

Car-roll	NULL
,	NULL
and	NULL
A.A.	NULL
Woodcock	NULL
.	NULL

1995	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
replication	NULL
within	NULL
pulmonary	NULL
epithelial	NULL
cells	NULL
in	NULL
cryptogenic	NULL
fibros	NULL
ing	NULL
alveolitis	NULL
.	NULL

Thorax	NULL
.	NULL

50:1234-1239	NULL
.	NULL

Borysiewicz	NULL
,	NULL
LK	NULL
.	NULL

,	NULL
J.K.	NULL
Hickling	NULL
,	NULL
S.	NULL
Graham	NULL
,	NULL
J.	NULL
Sinclair	NULL
,	NULL
M.P	NULL
.	NULL

Cranage	NULL
,	NULL
G.L	NULL
.	NULL

Smith	NULL
,	NULL
and	NULL
J.G.P	NULL
.	NULL

Sissons	NULL
.	NULL

1988	NULL
.	NULL

Human	NULL
cy-tomegalovirus-specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
Relative	NULL
frequency	NULL
of	NULL
stage-specific	NULL
CTL	NULL
recognizing	NULL
the	NULL
72-kD	NULL
immediate	NULL
early	NULL
protein	NULL
and	NULL
glycoprotein	NULL
B	NULL
expressed	NULL
by	NULL
recombinant	NULL
vaccinia	NULL
viruses	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

168:919-931	NULL
.	NULL

Riddell	NULL
,	NULL
S.R	NULL
.	NULL

,	NULL
M.	NULL
Rabin	NULL
,	NULL
A.P	NULL
.	NULL

Geballe	NULL
,	NULL
W.J	NULL
.	NULL

Britt	NULL
,	NULL
and	NULL
P.D	NULL
.	NULL

Greenberg	NULL
.	NULL

1991	NULL
.	NULL

Class-I	NULL
MHC	NULL
-restricted	NULL
cytotoxic	NULL
lympho-cyte-T	NULL
recognition	NULL
of	NULL
cells	NULL
infected	NULL
with	NULL
human	NULL
cytomegalovirus	NULL
does	NULL
not	NULL
require	NULL
endogenous	NULL
viral	NULL
gene	NULL
expression	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

146:2795-2804	NULL
.	NULL

Tigges	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
D.	NULL
Koelle	NULL
,	NULL
K.	NULL
Hartog	NULL
,	NULL
R.E	NULL
.	NULL

Sekulovich	NULL
,	NULL
L.	NULL
Corey	NULL
,	NULL
and	NULL
R.L	NULL
.	NULL

Burke	NULL
.	NULL

1992	NULL
.	NULL

Human	NULL
CD8+	NULL
herpes	NULL
simplex	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
clones	NULL
recognise	NULL
diverse	NULL
virion	NULL
protein	NULL
antigens	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

66:1622-1634	NULL
.	NULL

Gilbert	NULL
,	NULL
M.J.	NULL
,	NULL
SR.	NULL
Riddell	NULL
,	NULL
C.-R.	NULL
Li	NULL
,	NULL
and	NULL
P.D	NULL
.	NULL

Greenberg	NULL
.	NULL

1993	NULL
.	NULL

Selective	NULL
interference	NULL
with	NULL
class	NULL
I	NULL
major	NULL
histocompatability	NULL
complex	NULL
presentation	NULL
of	NULL
the	NULL
major	NULL
immediate-early	NULL
protein	NULL
following	NULL
infection	NULL
with	NULL
human	NULL
cytomegalovirus	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

67:3461-3469	NULL
.	NULL

York	NULL
,	NULL
LA	NULL
.	NULL

,	NULL
C.	NULL
Roop	NULL
,	NULL
D.W.	NULL
Andrews	NULL
,	NULL
S.	NULL
Riddell	NULL
,	NULL
F.	NULL
Graham	NULL
,	NULL
and	NULL
D.C.	NULL
Johnson	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
cytosolic	NULL
herpes	NULL
simplex	NULL
virus	NULL
protein	NULL
inhibits	NULL
antigen	NULL
presentation	NULL
to	NULL
CD8+	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
.	NULL

77:525-535	NULL
.	NULL

Hill	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Jugovic	NULL
,	NULL
I.	NULL
York	NULL
,	NULL
G.	NULL
R	NULL
uss	NULL
,	NULL
J.	NULL
Bennink	NULL
,	NULL
J.	NULL
Yewdell	NULL
,	NULL
H.	NULL
Ploegh	NULL
,	NULL
and	NULL
D.	NULL
Johnson	NULL
.	NULL

1995	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
turns	NULL
off	NULL
the	NULL
TAP	NULL
to	NULL
evade	NULL
host	NULL
immunity	NULL
.	NULL

Natwre	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

375	NULL
:	NULL
411-415	NULL
.	NULL

Fruh	NULL
,	NULL
K.	NULL
,	NULL
K.	NULL
Ahn	NULL
,	NULL
H.	NULL
Djaballah	NULL
,	NULL
P.	NULL
Sempe	NULL
,	NULL
P.M.	NULL
van	NULL
Endert	NULL
,	NULL
R.	NULL
Tampe	NULL
,	NULL
P.A	NULL
.	NULL

Peterson	NULL
,	NULL
and	NULL
Y.	NULL
Yang	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
viral	NULL
inhibi-tor	NULL
of	NULL
peptide	NULL
transporters	NULL
for	NULL
antigen	NULL
presentation	NULL
.	NULL

Nature	NULL
21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

375:415-418	NULL
.	NULL

Jones	NULL
,	NULL
TR	NULL
.	NULL

,	NULL
LK	NULL
.	NULL

Hanson	NULL
,	NULL
L.	NULL
Sun	NULL
,	NULL
J.S	NULL
.	NULL

Slater	NULL
,	NULL
R.M	NULL
.	NULL

Stenberg	NULL
,	NULL
and	NULL
A.E	NULL
.	NULL

Campbell	NULL
.	NULL

1995	NULL
.	NULL

Multiple	NULL
independent	NULL
loci	NULL
within	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
unique	NULL
short	NULL
region	NULL
down-regu-late	NULL
expression	NULL
of	NULL
major	NULL
histocompatability	NULL
complex	NULL
class	NULL
I	NULL
heavy	NULL
chains	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

69:4830-4841	NULL
.	NULL

Wiertz	NULL
,	NULL
EJ.H.J	NULL
.	NULL

,	NULL
TR	NULL
.	NULL

Jones	NULL
,	NULL
L.	NULL
Sun	NULL
,	NULL
M.	NULL
Bogyo	NULL
,	NULL
H.J	NULL
.	NULL

Geuze	NULL
,	NULL
and	NULL
H.L	NULL
.	NULL

Ploegh	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
human	NULL
cytomegalovirus	NULL
USI11	NULL
gene	NULL
product	NULL
dislocates	NULL
MHC	NULL
class	NULL
I	NULL
heavy	NULL
chains	NULL
from	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
to	NULL
the	NULL
cytosol	NULL
.	NULL

Céll	NULL
.	NULL

84:769-779	NULL
.	NULL

Kieff	NULL
,	NULL
E.	NULL
1996	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
and	NULL
its	NULL
replication	NULL
.	NULL

In	NULL
Fields	NULL
Virology	NULL
.	NULL

B.N	NULL
.	NULL

Fields	NULL
,	NULL
D.M	NULL
.	NULL

Knipe	NULL
,	NULL
and	NULL
P.M.	NULL
Howley	NULL
,	NULL
editors	NULL
.	NULL

Lippincott-R	NULL
aven	NULL
Publishers	NULL
,	NULL
Philadelphia	NULL
.	NULL

2343-2396	NULL
.	NULL

Rickinson	NULL
,	NULL
A.B	NULL
.	NULL

,	NULL
and	NULL
D.J	NULL
.	NULL

Moss	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
responses	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
infection	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

In	NULL
press	NULL
.	NULL

Biggin	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Bodescot	NULL
,	NULL
M.	NULL
Perricaudet	NULL
,	NULL
and	NULL
P.J	NULL
.	NULL

Farrell	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
gene	NULL
expression	NULL
in	NULL
P3HR	NULL
1-super-infected	NULL
R	NULL
aji	NULL
cells	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

61:3120-3132	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Y.	NULL
Ono	NULL
.	NULL

1989	NULL
.	NULL

Synchronous	NULL
and	NULL
sequential	NULL
activation	NULL
of	NULL
latently	NULL
infected	NULL
Epstein-Barr	NULL
virus	NULL
genomes	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:445-449	NULL
.	NULL

Cox	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.M	NULL
.	NULL

Hardwick	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
enhancer	NULL
within	NULL
the	NULL
divergent	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
responds	NULL
synergistically	NULL
to	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
J	NULL
Vimo	NULL
)	NULL
64	NULL
:	NULL
313-321	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.-C.	NULL
Mar	NULL
,	NULL
and	NULL
M.	NULL
Smith	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
BMLFI1	NULL
promoter	NULL
contains	NULL
an	NULL
enhancer	NULL
element	NULL
that	NULL
is	NULL
responsive	NULL
to	NULL
the	NULL
BZLFI1	NULL
and	NULL
BRLFI	NULL
transactivators	NULL
.	NULL

J	NULL
Vim	NULL
.	NULL

63:3878-3883	NULL
.	NULL

Holley-Guthrie	NULL
,	NULL
EA	NULL
.	NULL

,	NULL
E.B	NULL
.	NULL

Quinlivan	NULL
,	NULL
E.-C.	NULL
Mar	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
BMRFI	NULL
promoter	NULL
for	NULL
early	NULL
antigen	NULL
(	NULL
EA-D	NULL
)	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
EBV	NULL
trans	NULL
activators	NULL
,	NULL
BRLFI	NULL
and	NULL
BZLF1	NULL
,	NULL
in	NULL
a	NULL
cell-specific	NULL
manner	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

64:3753-3759	NULL
.	NULL

Bogedain	NULL
,	NULL
C.	NULL
,	NULL
H.	NULL
Wolf	NULL
,	NULL
S.	NULL
Modrow	NULL
,	NULL
G.	NULL
Stuber	NULL
,	NULL
and	NULL
W.	NULL
Jilg	NULL
.	NULL

1995	NULL
.	NULL

Specific	NULL
cytotoxic	NULL
T-lymphocytes	NULL
recognize	NULL
the	NULL
immediate-early	NULL
transactivator	NULL
ZTA	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J	NULL
Virol	NULL
69:4872-4879	NULL
.	NULL

Young	NULL
,	NULL
LS	NULL
.	NULL

,	NULL
R.	NULL
Lau	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
G.	NULL
Niedobitek	NULL
,	NULL
G.	NULL
Packham	NULL
,	NULL
F.	NULL
Shanahan	NULL
,	NULL
D.T	NULL
.	NULL

Rowe	NULL
,	NULL
D.	NULL
Greenspan	NULL
,	NULL
J.S	NULL
.	NULL

Greenspan	NULL
,	NULL
A.B	NULL
.	NULL

Rickinson	NULL
,	NULL
and	NULL
P.J	NULL
.	NULL

Farrell	NULL
.	NULL

1991	NULL
.	NULL

Differentiation-associ-ated	NULL
expression	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLFI1	NULL
transactivator	NULL
protein	NULL
in	NULL
oral	NULL
hairy	NULL
leukoplakia	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

65:2868-2874	NULL
.	NULL

Vroman	NULL
,	NULL
B.	NULL
,	NULL
J.	NULL
Luka	NULL
,	NULL
M.	NULL
Rodriguez	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Pearson	NULL
.	NULL

1985	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
major	NULL
protein	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
160,000	NULL
associated	NULL
with	NULL
the	NULL
viral	NULL
capsid	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

52:107-113	NULL
.	NULL

Hill	NULL
,	NULL
A.B	NULL
.	NULL

,	NULL
S.P	NULL
.	NULL

Lee	NULL
,	NULL
J.S	NULL
.	NULL

Haurum	NULL
,	NULL
N.	NULL
Murray	NULL
,	NULL
Q.Y	NULL
.	NULL

Yao	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
N.	NULL
Signoret	NULL
,	NULL
A.B	NULL
.	NULL

Rickinson	NULL
,	NULL
and	NULL
A.J	NULL
.	NULL

McMichael	NULL
.	NULL

1995	NULL
.	NULL

Class	NULL
I	NULL
major	NULL
histocompatibility	NULL
complex-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
specific	NULL
for	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
antigens	NULL
fail	NULL
to	NULL
lyse	NULL
the	NULL
EBV-transformed	NULL
B	NULL
lymphoblastoid	NULL
lines	NULL
against	NULL
which	NULL
they	NULL
were	NULL
raised	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:2221-2228	NULL
.	NULL

Lear	NULL
,	NULL
A.L	NULL
.	NULL

,	NULL
M.	NULL
Rowe	NULL
,	NULL
M.G	NULL
.	NULL

Kurilla	NULL
,	NULL
S.	NULL
Lee	NULL
,	NULL
S.	NULL
Henderson	NULL
,	NULL
E.	NULL
Kieff	NULL
,	NULL
and	NULL
A.B	NULL
.	NULL

Rickinson	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
nuclear	NULL
antigen	NULL
1	NULL
BamHI	NULL
F	NULL
promoter	NULL
is	NULL
activated	NULL
on	NULL
entry	NULL
of	NULL
EBV-transformed	NULL
B	NULL
cells	NULL
into	NULL
the	NULL
lytic	NULL
cycle	NULL
.	NULL

J	NULL
Vim	NULL
66:7461-7468	NULL
.	NULL

Burrows	NULL
,	NULL
S.R	NULL
.	NULL

,	NULL
A.	NULL
Suhrbier	NULL
,	NULL
R.	NULL
Khanna	NULL
,	NULL
and	NULL
D.J	NULL
.	NULL

Moss	NULL
.	NULL

1992	NULL
.	NULL

Rapid	NULL
visual	NULL
assay	NULL
of	NULL
cytotoxic	NULL
T-cell	NULL
specificity	NULL
utilizing	NULL
synthetic	NULL
peptide	NULL
induced	NULL
T-cell-T	NULL
-cell	NULL
killing	NULL
.	NULL

Immunol-	NULL
1616	NULL
36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50.	NULL
ogy	NULL
.	NULL

76:174-175	NULL
.	NULL

Burrows	NULL
,	NULL
SR.	NULL
,	NULL
T.B	NULL
.	NULL

Sculley	NULL
,	NULL
.S	NULL
.	NULL

Misko	NULL
,	NULL
C.	NULL
Schmidt	NULL
,	NULL
and	NULL
D.J	NULL
.	NULL

Moss	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
cell	NULL
epitope	NULL
in	NULL
EBNA3	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

171:345-350	NULL
.	NULL

Burrows	NULL
,	NULL
SR.	NULL
,	NULL
J.	NULL
Gardner	NULL
,	NULL
R.	NULL
Khanna	NULL
,	NULL
T.	NULL
Steward	NULL
,	NULL
D.J	NULL
.	NULL

Moss	NULL
,	NULL
S.	NULL
Rodda	NULL
,	NULL
and	NULL
A.	NULL
Suhrbier	NULL
.	NULL

1994	NULL
.	NULL

Five	NULL
new	NULL
cytotoxic	NULL
T-cell	NULL
epitopes	NULL
identified	NULL
within	NULL
Epstein-Barr	NULL
virus	NULL
nuclear	NULL
antigen	NULL
3	NULL
.	NULL

J	NULL
Gen.	NULL
Virol	NULL
.	NULL

75:2489-2493	NULL
.	NULL

Falk	NULL
,	NULL
K.	NULL
,	NULL
O.	NULL
Rotzschke	NULL
,	NULL
B.	NULL
Grahovac	NULL
,	NULL
D.	NULL
Schendel	NULL
,	NULL
S.	NULL
Sta-vanovic	NULL
,	NULL
V.	NULL
Gnau	NULL
,	NULL
G.	NULL
Jung	NULL
,	NULL
JL	NULL
.	NULL

Strominger	NULL
,	NULL
and	NULL
H.-G.	NULL
Rammensee	NULL
.	NULL

1993	NULL
.	NULL

Allele-specific	NULL
peptide	NULL
ligand	NULL
motifs	NULL
of	NULL
HLA-C	NULL
molecules	NULL
Proc	NULL
Natl	NULL
Aad	NULL
.	NULL

Sa	NULL
.	NULL

USA	NULL
.	NULL

90:12005-12009	NULL
.	NULL

Hunt	NULL
,	NULL
D.F	NULL
.	NULL

,	NULL
R.A.	NULL
Henderson	NULL
,	NULL
J.	NULL
Shabanowitz	NULL
,	NULL
K.	NULL
Sakaguchi	NULL
,	NULL
H.	NULL
Michel	NULL
,	NULL
N.	NULL
Sevilir	NULL
,	NULL
AL	NULL
.	NULL

Cox	NULL
,	NULL
E.	NULL
Appella	NULL
,	NULL
and	NULL
V.H	NULL
.	NULL

En-gelhard	NULL
.	NULL

1992	NULL
.	NULL

Characterization	NULL
of	NULL
peptides	NULL
bound	NULL
to	NULL
the	NULL
class	NULL
I	NULL
MHC	NULL
molecule	NULL
HLA-A2.1	NULL
by	NULL
mass	NULL
spectrometry	NULL
.	NULL

Sdene	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

255:1261-1263	NULL
.	NULL

Sutkowski	NULL
,	NULL
N.	NULL
,	NULL
T.	NULL
Palkama	NULL
,	NULL
C.	NULL
Ciurli	NULL
,	NULL
R.-P.	NULL
Sekaly	NULL
,	NULL
D.A	NULL
.	NULL

Thorley-Lawson	NULL
,	NULL
and	NULL
B.T	NULL
.	NULL

Huber	NULL
.	NULL

1996	NULL
.	NULL

An	NULL
Epstein-Barr	NULL
vi-rus-associated	NULL
superantigen	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:971-980	NULL
.	NULL

Callan	NULL
,	NULL
M.F.C	NULL
.	NULL

,	NULL
N.	NULL
Steven	NULL
,	NULL
P.	NULL
Krausa	NULL
,	NULL
J.D.K	NULL
.	NULL

Wilson	NULL
,	NULL
P.A.H	NULL
.	NULL

Moss	NULL
,	NULL
G.	NULL
M.	NULL
Gillespie	NULL
,	NULL
J.I	NULL
.	NULL

Bell	NULL
,	NULL
A.B	NULL
.	NULL

R	NULL
ickinson	NULL
,	NULL
and	NULL
A.J	NULL
.	NULL

McMichael	NULL
.	NULL

1996	NULL
.	NULL

Large	NULL
clonal	NULL
expansions	NULL
of	NULL
CD8+*	NULL
T	NULL
cells	NULL
in	NULL
acute	NULL
infectious	NULL
mononucleosis	NULL
Na	NULL
.	NULL

Med	NULL
.	NULL

2:906-911	NULL
.	NULL

Townsend	NULL
,	NULL
A.	NULL
,	NULL
J.	NULL
Bastin	NULL
,	NULL
K.	NULL
Gould	NULL
,	NULL
G.	NULL
Brownlee	NULL
,	NULL
A.	NULL
An-drew	NULL
,	NULL
D.B	NULL
.	NULL

Boyle	NULL
,	NULL
Y.	NULL
Chan	NULL
,	NULL
and	NULL
G.	NULL
Smith	NULL
.	NULL

1988	NULL
.	NULL

Defective	NULL
presentation	NULL
to	NULL
class	NULL
I-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
in	NULL
vaccinia-infected	NULL
cells	NULL
is	NULL
overcome	NULL
by	NULL
enhanced	NULL
degradation	NULL
of	NULL
antigens	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

168:1211-1224	NULL
.	NULL

Blake	NULL
,	NULL
N.W	NULL
.	NULL

,	NULL
S.	NULL
Kettle	NULL
,	NULL
KM	NULL
.	NULL

Law	NULL
,	NULL
K.	NULL
Gould	NULL
,	NULL
J.	NULL
Bastin	NULL
,	NULL
R.M	NULL
.	NULL

Townsend	NULL
,	NULL
and	NULL
G.L	NULL
.	NULL

Smith	NULL
.	NULL

1995	NULL
.	NULL

Vaccinia	NULL
virus	NULL
serpins	NULL
B13R	NULL
and	NULL
B22R	NULL
do	NULL
not	NULL
inhibit	NULL
antigen	NULL
presentation	NULL
to	NULL
class	NULL
I-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
Gen.	NULL
Viml	NULL
.	NULL

76:2393-2398	NULL
.	NULL

Lieberman	NULL
,	NULL
P.M.	NULL
,	NULL
P.	NULL
O'Hare	NULL
,	NULL
G.S	NULL
.	NULL

Hayward	NULL
,	NULL
and	NULL
S.D	NULL
.	NULL

Hay-ward	NULL
.	NULL

1986	NULL
.	NULL

Promiscuous	NULL
tms	NULL
activation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
an	NULL
Epstein-Barr	NULL
virus-encoded	NULL
early	NULL
nuclear	NULL
protein	NULL
.	NULL

J	NULL
Virol	NULL
.	NULL

60:140-148	NULL
.	NULL

Kiehl	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
D.I	NULL
.	NULL

Dorsky	NULL
.	NULL

1991	NULL
.	NULL

Co-operation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
DNA	NULL
polymerase	NULL
and	NULL
EA-D	NULL
(	NULL
BMRF1	NULL
)	NULL
in	NULL
vitro	NULL
and	NULL
colocalization	NULL
in	NULL
nuclei	NULL
of	NULL
infected	NULL
cells	NULL
.	NULL

Vimlogy	NULL
.	NULL

184:330-340	NULL
.	NULL

Neubling	NULL
,	NULL
C.M	NULL
.	NULL

,	NULL
and	NULL
N.	NULL
Mueller-Lantzsch	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
and	NULL
characterisation	NULL
of	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
antigen	NULL
that	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
Not1	NULL
repeats	NULL
.	NULL

J	NULL
Virol	NULL
63:4609-4615	NULL
.	NULL

Pearson	NULL
,	NULL
G.R	NULL
.	NULL

,	NULL
J.	NULL
Luka	NULL
,	NULL
L.	NULL
Petti	NULL
,	NULL
J	NULL
.	NULL

Sample	NULL
,	NULL
M.	NULL
Birkenbach	NULL
,	NULL
D.	NULL
Braun	NULL
,	NULL
and	NULL
E.	NULL
Kieff	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
gene	NULL
encoding	NULL
a	NULL
second	NULL
component	NULL
of	NULL
the	NULL
restricted	NULL
early	NULL
antigen	NULL
complex	NULL
.	NULL

Vimlogy	NULL
.	NULL

160:151-161	NULL
.	NULL

White	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
SM	NULL
.	NULL

Cross	NULL
,	NULL
M.G	NULL
.	NULL

Kurilla	NULL
,	NULL
BM	NULL
.	NULL

Kerr	NULL
,	NULL
C.	NULL
Schmidt	NULL
,	NULL
I.S	NULL
.	NULL

Misko	NULL
,	NULL
R.	NULL
Khanna	NULL
,	NULL
and	NULL
D.J	NULL
.	NULL

Moss	NULL
.	NULL

1996	NULL
.	NULL

Recruitment	NULL
during	NULL
infectious	NULL
mononucleosis	NULL
of	NULL
CD3+	NULL
CD4+	NULL
CD8+	NULL
virus-specific	NULL
cytotoxic	NULL
T	NULL
cells	NULL
which	NULL
recognise	NULL
Ep-stein-	NULL
Barr	NULL
virus	NULL
lytic	NULL
antigen	NULL
BHRFI	NULL
.	NULL

Vimlogy	NULL
.	NULL

219:489-492	NULL
.	NULL

Scotet	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
David-Ameline	NULL
,	NULL
M.-A	NULL
.	NULL

Peyrat	NULL
,	NULL
A.	NULL
Moreau-Aubry	NULL
,	NULL
D.	NULL
Pinczon	NULL
,	NULL
A.	NULL
Lim	NULL
,	NULL
J	NULL
.	NULL

Even	NULL
,	NULL
G.	NULL
Semana	NULL
,	NULL
J.M	NULL
.	NULL

Ber-thelot	NULL
,	NULL
R	NULL
.	NULL

Breathnach	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
.	NULL

T	NULL
cell	NULL
response	NULL
to	NULL
Epstein-Barr	NULL
virus	NULL
transactivators	NULL
in	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
.	NULL

J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:1791-1800	NULL
.	NULL

Schendel	NULL
,	NULL
D.J	NULL
.	NULL

,	NULL
C.	NULL
Reinhardt	NULL
,	NULL
P.J	NULL
.	NULL

Nelson	NULL
,	NULL
B.	NULL
Maget	NULL
,	NULL
L.	NULL
Pullen	NULL
,	NULL
G.	NULL
W.	NULL
Bornkamm	NULL
,	NULL
and	NULL
A.	NULL
Steinle	NULL
.	NULL

1992	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocytes	NULL
show	NULL
HLA-C-restricted	NULL
recognition	NULL
of	NULL
EBV	NULL
CTL	NULL
Responses	NULL
to	NULL
Epstein-Barr	NULL
Virus	NULL
Lytic	NULL
Cycle	NULL
Antigens	NULL
51	NULL
.	NULL

52	NULL
.	NULL

53.	NULL
bearing	NULL
cells	NULL
and	NULL
allorecognition	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
molecules	NULL
presenting	NULL
self	NULL
peptides	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

149:2406-2414	NULL
.	NULL

Zemmour	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
Parham	NULL
.	NULL

1992	NULL
.	NULL

Distinctive	NULL
polymor-phism	NULL
at	NULL
the	NULL
HLA-C	NULL
locus	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
HLA-C.	NULL
J	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:937-950	NULL
.	NULL

Yao	NULL
,	NULL
Q.Y	NULL
.	NULL

,	NULL
A.B	NULL
.	NULL

Rickinson	NULL
,	NULL
J.S.H	NULL
.	NULL

Gaston	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Epstein	NULL
.	NULL

1985	NULL
.	NULL

In	NULL
vitro	NULL
analysis	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
:	NULL
host	NULL
balance	NULL
in	NULL
long-term	NULL
renal	NULL
allograft	NULL
recipients	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
Caner	NULL
.	NULL

35:43-49	NULL
.	NULL

Gilbert	NULL
,	NULL
M.	NULL
,	NULL
SR.	NULL
Riddell	NULL
,	NULL
B.	NULL
Plachter	NULL
,	NULL
and	NULL
R.D	NULL
.	NULL

Greenberg	NULL
.	NULL

1617	NULL
Steven	NULL
et	NULL
al	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

1996	NULL
.	NULL

Cytomegalovirus	NULL
selectively	NULL
blocks	NULL
antigen	NULL
processing	NULL
and	NULL
presentation	NULL
of	NULL
its	NULL
immediate-early	NULL
gene	NULL
product	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

383:720-722	NULL
.	NULL

Whitley	NULL
,	NULL
R.J.	NULL
1996	NULL
.	NULL

Herpes	NULL
simplex	NULL
viruses	NULL
.	NULL

In	NULL
Fields	NULL
Virology	NULL
.	NULL

B.N	NULL
.	NULL

Fields	NULL
,	NULL
D.M	NULL
.	NULL

Knipe	NULL
,	NULL
and	NULL
P.M.	NULL
Howley	NULL
,	NULL
editors	NULL
.	NULL

Lippincott-R	NULL
aven	NULL
Publishers	NULL
,	NULL
Philadelphia	NULL
.	NULL

2297-2342	NULL
.	NULL

Yao	NULL
,	NULL
Q.Y	NULL
.	NULL

,	NULL
A.B	NULL
.	NULL

Rickinson	NULL
,	NULL
and	NULL
M.A	NULL
.	NULL

Epstein	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
re-examination	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
carrier	NULL
state	NULL
in	NULL
healthy	NULL
seropositive	NULL
individuals	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
Caner	NULL
.	NULL

35:35-42	NULL
.	NULL

